<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biology (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Biology (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2312</journal-id><journal-id journal-id-type="pmc-domain">biology</journal-id><journal-id journal-id-type="publisher-id">biology</journal-id><journal-title-group><journal-title>Biology</journal-title></journal-title-group><issn pub-type="epub">2079-7737</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9687436</article-id><article-id pub-id-type="pmcid-ver">PMC9687436.1</article-id><article-id pub-id-type="pmcaid">9687436</article-id><article-id pub-id-type="pmcaiid">9687436</article-id><article-id pub-id-type="pmid">36421377</article-id><article-id pub-id-type="doi">10.3390/biology11111662</article-id><article-id pub-id-type="publisher-id">biology-11-01662</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8581-4809</contrib-id><name name-style="western"><surname>Sano</surname><given-names initials="H">Hiroyuki</given-names></name><xref rid="c1-biology-11-01662" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Imagawa</surname><given-names initials="A">Akihisa</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Nagafuchi</surname><given-names initials="S">Seiho</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biology-11-01662">Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan</aff><author-notes><corresp id="c1-biology-11-01662"><label>*</label>Correspondence: <email>hiroyuki.sano@ompu.ac.jp</email>; Tel.: +81-72-683-1221</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2022</year></pub-date><volume>11</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">419896</issue-id><elocation-id>1662</elocation-id><history><date date-type="received"><day>06</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>25</day><month>11</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-30 00:25:09.067"><day>30</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="biology-11-01662.pdf"/><abstract><sec><title>Simple Summary</title><p>From 2019, coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread worldwide and became a serious problem. It is known that various viruses are involved in the development of type 1 diabetes (T1D), but the reports of an association between SARS-CoV-2 and T1D are mixed. Fulminant type 1 diabetes (FT1D) is a subtype of T1D mainly reported from East Asia. Autoimmune type 1 diabetes (AT1D) is characterized by chronic pancreatic &#946;-cell destruction, whereas FT1D is characterized by rapid and almost complete islet destruction following flu-like symptoms, leading to ketoacidosis and, in some cases, sudden death. When discussing the association between COVID-19 and T1D, it is also necessary to focus on FT1D. However, it is not easy to diagnose this subtype without understanding the concept. Therefore, the authors hereby review the concept and latest findings, hoping that the association between COVID-19 and T1D will be adequately evaluated in the future.</p></sec><sec><title>Abstract</title><p>Fulminant type 1 diabetes (FT1D) is a subtype of type 1 diabetes (T1D) that is characterized by the rapid progression to diabetic ketoacidosis against the background of rapid and almost complete pancreatic islet destruction. The HbA1c level at FT1D onset remains normal or slightly elevated despite marked hyperglycemia, reflecting the rapid clinical course of the disease, and is an important marker for diagnosis. FT1D often appears following flu-like symptoms, and there are many reports of its onset being linked to viral infections. In addition, disease-susceptibility genes have been identified in FT1D, suggesting the involvement of host factors in disease development. In most cases, islet-related autoantibodies are not detected, and histology of pancreatic tissue reveals macrophage and T cell infiltration of the islets in the early stages of FT1D, suggesting that islet destruction occurs via an immune response different from that occurring in autoimmune type 1 diabetes. From 2019, coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread worldwide and became a serious problem. Reports on the association between SARS-CoV-2 and T1D are mixed, with some suggesting an increase in T1D incidence due to the COVID-19 pandemic. When discussing the association between COVID-19 and T1D, it is also necessary to focus on FT1D. However, it is not easy to diagnose this subtype without understanding the concept. Therefore, authors hereby review the concept and the latest findings of FT1D, hoping that the association between COVID-19 and T1D will be adequately evaluated in the future.</p></sec></abstract><kwd-group><kwd>fulminant type 1 diabetes</kwd><kwd>autoimmune type 1 diabetes</kwd><kwd>coronavirus disease 2019</kwd><kwd>severe acute respiratory syndrome coronavirus-2</kwd><kwd>enterovirus</kwd><kwd>innate immunity</kwd><kwd>acquired immunity</kwd></kwd-group><funding-group><funding-statement>This review received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-biology-11-01662"><title>1. Introduction</title><p>Type 1 diabetes (T1D) is characterized by almost absolute insulin deficiency due to the destruction of pancreatic &#946;-cells. Most cases of diabetes are autoimmune type 1 diabetes (AT1D), which is positive for islet-related autoantibodies, and the period from the onset of diabetes symptoms to diabetic ketoacidosis (DKA) ranges from a few weeks to several months. Another form is idiopathic type 1 diabetes, in which islet-related autoantibodies are not detected. In 2000, another idiopathic subtype called fulminant type 1 diabetes (FT1D) with an extremely rapid course was reported [<xref rid="B1-biology-11-01662" ref-type="bibr">1</xref>]. Autopsy tissue from patients who died immediately after FT1D onset showed macrophages and T cells infiltrating the islets, and in some cases, enteroviruses were detected in the islets [<xref rid="B2-biology-11-01662" ref-type="bibr">2</xref>]. Furthermore, pancreatic biopsies performed 1&#8211;5 months after onset showed that the islets had almost disappeared, suggesting that they had been destroyed completely in a short period of time [<xref rid="B1-biology-11-01662" ref-type="bibr">1</xref>]. Typical FT1D cases are characterized by DKA after a few days of flu-like or gastrointestinal symptoms, and some patients die suddenly after being diagnosed with the common cold. Considering the probable association of FT1D with not only enteroviruses but also other viral infections, it is important to monitor the impact of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) on the incidence of FT1D and to raise global awareness of FT1D. Therefore, this review summarizes the overview and recent findings of FT1D so as not to overlook COVID-19 associated FT1D.</p></sec><sec id="sec2-biology-11-01662"><title>2. Clinical Characteristics</title><p>To date, most reported FT1D cases have been from East Asia, particularly Japan. FT1D accounts for approximately 20% of newly diagnosed T1D with ketosis or ketoacidosis in Japan [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>], making it an important subtype for investigation. It was reported that FT1D accounted for 7.1% of newly diagnosed T1D patients in South Korea and 1.5&#8211;5.5% in China [<xref rid="B4-biology-11-01662" ref-type="bibr">4</xref>,<xref rid="B5-biology-11-01662" ref-type="bibr">5</xref>] In Japan, there is no official registration for T1D, so it is difficult to know the exact number of patients with T1D. In the Ehime study, a regional hospital-based study for diabetes, the prevalence of FT1D was reported to be 8.9% in all T1D patients and 0.2% in consecutive 4980 newly diagnosed diabetes patients in Japan [<xref rid="B6-biology-11-01662" ref-type="bibr">6</xref>]. In 2009, Japan was estimated to have 5000 to 7000 FT1D patients based on the estimated number of diabetes patients at that time, the data from the Ehime study, and the data based on multicenter joint research of FT1D [<xref rid="B7-biology-11-01662" ref-type="bibr">7</xref>]. Recently, from 2016 to 2017, the Japanese Ministry of Health, Labor, and Welfare estimates that there were around ten million diabetes patients and approximately 120,000 T1D patients in Japan. Therefore, authors speculate that there are approximately 10,000 patients with FT1D in Japan now, and the number is increasing year by year [<xref rid="B8-biology-11-01662" ref-type="bibr">8</xref>].</p><p>According to the Japan Diabetes Society, AT1D is more common among women, whereas no sex-specific difference was observed in FT1D [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>]. More than 90% of FT1D patients have adult onset, and the mean age of onset is higher than that of AT1D [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>]. Approximately 72% of FT1D patients develop after flu-like symptoms and rapidly progress to DKA [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>]. The duration from initiation to completion of pancreatic &#946;-cell destruction is also speculated to be consistent with this short duration. In contrast, patients with AT1D usually progress to DKA approximately within three months after the onset of diabetic symptoms. Furthermore, pancreatic &#946;-cell destruction gradually progresses over several months before the onset of diabetic symptoms and continues after the onset (<xref rid="biology-11-01662-t001" ref-type="table">Table 1</xref>) [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>]. FT1D tends to be recognized as acute-onset T1D, which is mostly AT1D, because DKA appears acutely: however, the rapidity of destruction of pancreatic &#946;-cells in both is drastically different.</p><p>It has been reported that some patients who happened to develop FT1D during treatment for other diseases showed transient hypoglycemia and relatively high insulin levels shortly before the onset [<xref rid="B9-biology-11-01662" ref-type="bibr">9</xref>,<xref rid="B10-biology-11-01662" ref-type="bibr">10</xref>]. This interesting finding may reflect the rapid destruction of pancreatic &#946;-cells and insulin leakage. At the time of diagnosis, blood and urinary C-peptide levels are already very low, suggesting short-term severe pancreatic &#946;-cell destruction. In addition, glutamic acid decarboxylase antibody (GADAb), which is a representative serum marker used for the diagnosis of AT1D, has not been identified in most FT1D patients. In addition, some patients show elevated levels of exocrine pancreatic enzymes or acute pancreatitis; therefore, in FT1D, both islets and pancreatic acinar cells seem to be destroyed in different manners compared to their destruction in AT1D.</p><p>Patients with FT1D often consult a physician for flu-like or gastrointestinal symptoms and then develop DKA a few days later. Alternatively, when patients with FT1D who developed DKA consult a physician, they may be diagnosed with a common cold for the preceding flu-like symptoms. DKA is more severe in FT1D than in AT1D. Therefore, fatality is likely if diagnosis is delayed. On the other hand, some patients with FT1D may have been diagnosed with atypical T1D and not recognized as FT1D. To diagnose this T1D subtype, the Japan Diabetes Society has created criteria for definite FT1D diagnosis (<xref rid="biology-11-01662-t002" ref-type="table">Table 2</xref>) [<xref rid="B11-biology-11-01662" ref-type="bibr">11</xref>]. However, immune checkpoint inhibitors (ICIs), recently used as anti-cancer drugs, can cause atypical FT1D (ICI-related FT1D), which is one of the immune-related adverse events (irAEs) [<xref rid="B12-biology-11-01662" ref-type="bibr">12</xref>]. In such cases, caution is required in the use of this diagnostic criteria. Caution is also required in FT1D patients that develop in the course of type 2 diabetes because the HbA1c level at the onset is often high and one of the Japanese FT1D diagnostic criteria, &#8220;HbA1c &lt; 8.7,&#8221; cannot be applied. Therefore, the identification of biomarkers specific to FT1D is anticipated for more definitive diagnosis. Amylase alpha-2A and heat shock protein 10 (HSP10) autoantibodies that are detected in autoimmune pancreatitis are also commonly identified in FT1D and are being discussed as possible diagnostic markers. [<xref rid="B13-biology-11-01662" ref-type="bibr">13</xref>,<xref rid="B14-biology-11-01662" ref-type="bibr">14</xref>]. The comprehensive antibody analysis of FT1D patient serum found CD300e antibodies in the early stages after onset, suggesting their use as an early diagnostic marker [<xref rid="B15-biology-11-01662" ref-type="bibr">15</xref>]. CD300e is a molecule involved in immunoregulation of the surface markers of monocytes and dendritic cells; the significance of CD300e and its antibody is under investigation.</p></sec><sec id="sec3-biology-11-01662"><title>3. Treatment of FT1D</title><p>The treatment strategy of insulin therapy for FT1D is the same as that for AT1D. However, insulin secretion in AT1D patients is reduced but maintained for a certain period (even decades) after onset [<xref rid="B16-biology-11-01662" ref-type="bibr">16</xref>,<xref rid="B17-biology-11-01662" ref-type="bibr">17</xref>], whereas patients with FT1D have depleted insulin secretion capacity at diagnosis due to islet destruction [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>], which may lead to more unstable glycemic control than AT1D. A 2007 report by the Japan Diabetes Society stated that rates of microvascular complications 5 years after onset were more frequent in FT1D patients than in AT1D patients; this result may reflect glycemic instability and low C-peptide levels [<xref rid="B18-biology-11-01662" ref-type="bibr">18</xref>]. Moreover, when HbA1c levels and systolic blood pressure are managed properly, there is no difference in the frequency of microvascular complications between FT1D and AT1D patients [<xref rid="B19-biology-11-01662" ref-type="bibr">19</xref>]. We expect that the lower risk of complications will be facilitated by better treatment owing to new insulin formulations and devices such as sensor-augmented pumps (SAPs) and closed-loop systems.</p><p>The primary and available treatment of T1D is insulin therapy as mentioned above, and in some cases that meet the criteria, islet transplantation, pancreatic transplantation, and simultaneous pancreas and kidney transplantation are performed.</p><p>However, the future challenge in T1D is the establishment of immunotherapy that prevents the destruction of pancreatic &#946;-cells. Because more residual pancreatic &#946;-cells are beneficial for glycemic control and prognosis, establishing remission therapies for the early stage of AT1D and prevention therapies for high-risk individuals of AT1D is critical [<xref rid="B20-biology-11-01662" ref-type="bibr">20</xref>]; various trials have been performed. Tertiary prevention for new-onset patients with AT1D aims to preserve the remaining pancreatic &#946;-cells to induce and prolong partial remission. Several immunomodulatory and immunosuppressive agents, such as cyclosporine A, anti-CD3, cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-Ig, anti-CD20, and recombinant human glutamic acid decarboxylase formulated with aluminum hydroxide(rhGAD65-alum), have been investigated to prevent the destructive autoimmune process of pancreatic &#946;-cells that occurs in T1D [<xref rid="B21-biology-11-01662" ref-type="bibr">21</xref>,<xref rid="B22-biology-11-01662" ref-type="bibr">22</xref>,<xref rid="B23-biology-11-01662" ref-type="bibr">23</xref>,<xref rid="B24-biology-11-01662" ref-type="bibr">24</xref>,<xref rid="B25-biology-11-01662" ref-type="bibr">25</xref>,<xref rid="B26-biology-11-01662" ref-type="bibr">26</xref>,<xref rid="B27-biology-11-01662" ref-type="bibr">27</xref>]. Some trials have been successful in partially retaining residual pancreatic &#946;-cell function; however, patients with FT1D are not indicated for tertiary prevention because their pancreatic &#946;-cell function is already depleted at disease onset.</p><p>In AT1D, primary prevention trials for individuals with high-risk genotypes in which islet-associated autoantibodies have not yet emerged, and secondary prevention trials for individuals with islet-associated autoantibodies but without diabetes were conducted, some of which are currently ongoing. Of these, their effectiveness has been reported only in limited trials, such as secondary preventive trials using anti-CD3, and the results of other ongoing trials are expected [<xref rid="B28-biology-11-01662" ref-type="bibr">28</xref>]. However, in FT1D, there is no strategy to identify individuals at risk; thus, it is difficult to establish a primary or secondary prevention program.</p><p>The most important candidate virus for AT1D is the Coxsackie B virus. Vaccines against the Coxsackie B virus have recently been developed and have been shown to suppress Coxsackie B virus-induced diabetes in mice [<xref rid="B29-biology-11-01662" ref-type="bibr">29</xref>]. If the vaccine were applied to humans, it may be useful for the management of various diseases caused by Coxsackie B virus, including AT1D. </p><p>Since FT1D has also been suggested to be associated with enterovirus, including Coxsackie B, if the vaccine were widely used in humans to prevent Coxsackie B virus-associated diseases, it may also have contributed to the prevention of FT1D. However, the etiology of FT1D has not been fully elucidated and the cost-effectiveness of the vaccine must be considered. Therefore, the vaccine program against FT1D is a future challenge.</p></sec><sec id="sec4-biology-11-01662"><title>4. Etiology</title><sec id="sec4dot1-biology-11-01662"><title>4.1. Disease-Susceptibility Genes</title><p>Investigation using the candidate gene approach showed an association of FT1D with the class II human leukocyte antigen (<italic toggle="yes">HLA</italic>) gene, similar to AT1D. First, it was revealed that a high rate of 41.8% of Japanese FT1D patients possessed the HLA class II haplotype DR4-DQ4 [<xref rid="B30-biology-11-01662" ref-type="bibr">30</xref>]. Genotyping showed that the highest disease sensitivity was at <italic toggle="yes">DRB1*04:05-DQB1*04:01</italic>, followed by <italic toggle="yes">DRB1*09:01-DQB1*03:03</italic>, which are haplotypes that are also implicated in Japanese AT1D. In contrast, other sensitive and resistant haplotypes confirmed in AT1D have not been found to be associated with FT1D; these data indicate that there are similarities and differences in the HLA gene susceptibility between the two subtypes of type 1 diabetes. </p><p>In addition, GADAb were detected in approximately 5% of FT1D patients, in which DRB1*09:01-DQB1*03:03 exhibited sensitivity whereas DRB1*04:05-DQB1*04:01 did not [<xref rid="B31-biology-11-01662" ref-type="bibr">31</xref>]. Thus, the involvement of HLA in FT1D differs between cases that are positive or negative for GADAb. </p><p>Recently, the Japan Diabetes Society conducted a genome-wide association study (GWAS) in Japanese FT1D patients. In addition to showing the strongest association with class II HLA genes, which is already known, FT1D showed an association with the <italic toggle="yes">CSAD/lnc-ITGB7-1</italic> region in the long arm of chromosome 12 [<xref rid="B32-biology-11-01662" ref-type="bibr">32</xref>]. Furthermore, fine mapping identified multiple single nucleotide polymorphisms (SNPs) in this region [<xref rid="B32-biology-11-01662" ref-type="bibr">32</xref>]. These SNPs showed no association with AT1D; this result indicates their association with FT1D-specific pathologies.</p><p><italic toggle="yes">CSAD</italic> encodes cysteine sulfinic acid decarboxylase, a taurine synthase, and taurine is known to have antioxidant and anti-apoptotic effects. In animals, taurine has been reported to exert a cytoprotective action on pancreatic &#946;-cells during their destruction by streptozotocin [<xref rid="B33-biology-11-01662" ref-type="bibr">33</xref>]. Therefore, <italic toggle="yes">CSAD</italic> mutation may weaken the protective action of taurine on pancreatic &#946;-cells. </p><p>Furthermore, a long non-coding RNA, <italic toggle="yes">lnc-ITGB7-1</italic>, which affects the expression of <italic toggle="yes">ITGB-7</italic>, overlaps in the <italic toggle="yes">CSAD</italic> region. <italic toggle="yes">ITGB-7</italic> encodes integrin subunit beta 7, and the integrin &#946; chain is expressed on lymphocytes as a heterodimer with the &#945; chain. Additionally, mucosal addressin cell adhesion molecule-1 (MADCAM-1), which is expressed in areas of inflammation, is a ligand of ITGB-7 and involved in lymphocyte migration to areas of inflammation [<xref rid="B34-biology-11-01662" ref-type="bibr">34</xref>]. Therefore, SNPs in this region may also play a role in islet fragility and inflammation and thereby be associated with FT1D.</p></sec><sec id="sec4dot2-biology-11-01662"><title>4.2. Viruses and FT1D</title><p>As many FT1D patients develop after flu-like symptoms, viruses are strongly suspected to trigger the onset of this disease. In 2008, the Japan Diabetes Society analyzed paired serum from 38 FT1D patients and found that 7 of the 38 patients had elevated antibody levels for one or more of the following: coxsackievirus, rotavirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus (HHV)6, or HHV7 [<xref rid="B35-biology-11-01662" ref-type="bibr">35</xref>]. In fact, many cases have been reported wherein enterovirus, coxsackievirus, cytomegalovirus, HHV6, influenza virus B, mumps cold virus, EBV, and rotavirus were involved in the development of FT1D [<xref rid="B36-biology-11-01662" ref-type="bibr">36</xref>,<xref rid="B37-biology-11-01662" ref-type="bibr">37</xref>,<xref rid="B38-biology-11-01662" ref-type="bibr">38</xref>,<xref rid="B39-biology-11-01662" ref-type="bibr">39</xref>,<xref rid="B40-biology-11-01662" ref-type="bibr">40</xref>,<xref rid="B41-biology-11-01662" ref-type="bibr">41</xref>,<xref rid="B42-biology-11-01662" ref-type="bibr">42</xref>,<xref rid="B43-biology-11-01662" ref-type="bibr">43</xref>,<xref rid="B44-biology-11-01662" ref-type="bibr">44</xref>,<xref rid="B45-biology-11-01662" ref-type="bibr">45</xref>], and viral infection is considered to be the most important environmental risk factor for FT1D. </p><p>Although these viruses have a global distribution and infect people worldwide, FT1D mainly occurs in East Asia and in Japan, where the majority of FT1D cases have been reported to date.</p><p>A national survey in Japan found enterovirus IgA titers to be significantly higher in FT1D patients than in healthy individuals or AT1D patients and suggested the involvement of enteroviruses in FT1D pathophysiology [<xref rid="B46-biology-11-01662" ref-type="bibr">46</xref>]. This method of detecting enterovirus antibodies reacts with several different serotypes of enterovirus, such as coxsackie A, coxsackie B, and echo virus. Titers of IgA would be increased if different serotypes of enterovirus repeatedly infected a single patient. Thus, this result suggests that FT1D patients are more susceptible to enterovirus infections than others. It is interesting to agree with the report that enterovirus VP1 was detected in the autopsy pancreatic tissue of FT1D. Similar to FT1D, it has been pointed out that enterovirus, CMV [<xref rid="B47-biology-11-01662" ref-type="bibr">47</xref>], rotavirus [<xref rid="B48-biology-11-01662" ref-type="bibr">48</xref>] etc., are involved in AT1D, particularly the contribution of enterovirus is extensively supported [<xref rid="B49-biology-11-01662" ref-type="bibr">49</xref>].</p><p>Enteroviruses have been isolated from intestinal biopsy samples in 75% of T1D patients versus 10% of control patients, possibly reflecting persistent enterovirus infection of the gut mucosa [<xref rid="B50-biology-11-01662" ref-type="bibr">50</xref>]. The intestine, which is anatomically close to the pancreas, may contribute as a reservoir of enterovirus in T1D. Alternatively, initial immune recognition could occur in the intestine, followed by subsequent homing of activated lymphocytes into the pancreas [<xref rid="B50-biology-11-01662" ref-type="bibr">50</xref>].</p><p>The Diabetes Virus Detection study (DiViD) detected enterovirus in pancreatic tissue specimens from three of six T1D patients [<xref rid="B51-biology-11-01662" ref-type="bibr">51</xref>]. Further, enterovirus proteins, enterovirus RNA, and an active antiviral host response have been demonstrated in the pancreata of T1D donors from biobanks including the Network for Pancreatic Organ Donors with Diabetes (nPOD) [<xref rid="B52-biology-11-01662" ref-type="bibr">52</xref>]. These data suggest that enteroviruses are persistently or repetitively infected during the process of T1D.</p><p>The chronic autoimmune process of AT1D is defined by three stages of disease progression [<xref rid="B53-biology-11-01662" ref-type="bibr">53</xref>]. Stage 1 is seroconversion to one or more islet-related autoantibodies [<xref rid="B53-biology-11-01662" ref-type="bibr">53</xref>]. Stage 2 is damage to the pancreatic &#946;-cells causing pre-symptomatic hyperglycemia, and stage 3 is overt T1D due to pancreatic &#946;-cell failure with a requirement for exogenous insulin [<xref rid="B53-biology-11-01662" ref-type="bibr">53</xref>]. The association between enterovirus and AT1D can be summarized as follows. Inefficient viral clearance of enterovirus [<xref rid="B54-biology-11-01662" ref-type="bibr">54</xref>], cytokine response from pancreatic &#946;-cells and increased expression of MHC class I on pancreatic &#946;-cells cause or accelerate islet autoimmunity through molecular mimicry, inflammation, and bystander activation [<xref rid="B49-biology-11-01662" ref-type="bibr">49</xref>]. That is, enteroviruses have the ability to initiate islet autoimmunity and accelerate all three stages. Recently, it was demonstrated that enterovirus isolated from a newly diagnosed T1D patient could infect human islet cells and induce destruction in vitro [<xref rid="B55-biology-11-01662" ref-type="bibr">55</xref>].</p><p>From the above, it is considered that in sensitive individuals, enterovirus directly lyses pancreatic &#946;-cells to activate immunity, thereby leading to FT1D. However, further investigation is needed on the significance of repetitive enterovirus infections, the association with other viruses, and the reasons for the rapidity of islet destruction.</p></sec><sec id="sec4dot3-biology-11-01662"><title>4.3. Drug-Induced Hypersensitivity Syndrome (DIHS) and FT1D</title><p>DIHS is a form of severe drug eruption caused by certain drugs, including carbamazepine, allopurinol, lamotrigine, phenobarbital, and mexiletine. The use of these drugs leads to delayed-onset severe erythema, fever, liver dysfunction, and lymph node swelling, followed by the reactivation of HHV6 after 2&#8211;3 weeks, which is characteristic of DIHS and is accompanied by a variety of organ disorders, such as encephalitis, FT1D, and nephropathy [<xref rid="B56-biology-11-01662" ref-type="bibr">56</xref>,<xref rid="B57-biology-11-01662" ref-type="bibr">57</xref>]. </p><p>Treatment for DIHS is systemic steroid administration. However, steroids are not considered a major factor in viral reactivation, as reactivation of HHV6 has been observed even in steroid-na&#239;ve patients. At DIHS onset, an increase in the number of regulatory T cells and a decrease in the number of B cells have been observed, along with reduced serum IgG levels, suggesting that the state of transient immunodeficiency initially caused by the drug leads to reactivation of the virus [<xref rid="B58-biology-11-01662" ref-type="bibr">58</xref>]. Sugita et al. also speculated that the accumulation of dendritic cells in DIHS skin lesions reduces the number of dendritic cells in the blood, leading to reactivation of the virus [<xref rid="B59-biology-11-01662" ref-type="bibr">59</xref>]. HHV6 reactivation is followed by reactivation of the EBV, CMV, and varicella zoster virus (VZV) [<xref rid="B60-biology-11-01662" ref-type="bibr">60</xref>]. CMV-infected cells in pancreatic tissues of patients with FT1D that developed 3 weeks after DIHS have also been reported [<xref rid="B61-biology-11-01662" ref-type="bibr">61</xref>]. Additionally, effector T cells are activated against viruses, and various forms of organ damage can persist for long periods, even after viral clearance.</p><p>There have been many reports of FT1D following DIHS in Japan. According to a nationwide survey, the frequency of FT1D in DIHS is 0.54%, which is much higher than the rate of Japanese spontaneous occurring rate (0.01%) [<xref rid="B6-biology-11-01662" ref-type="bibr">6</xref>]. In many cases, FT1D onset is reported to occur after the eruption peak and during steroid tapering [<xref rid="B62-biology-11-01662" ref-type="bibr">62</xref>]. Therefore, an excessive immune response, which destroys the islets, is considered to occur due to the reactivation of a virus with an affinity for pancreatic &#946;-cells and the recovery of immune functions by stopping the causative drug or reducing the dose of steroid.</p></sec><sec id="sec4dot4-biology-11-01662"><title>4.4. COVID-19 and FT1D</title><p>Previous studies have shown that SARS-CoV-2 infects pancreatic endocrine and acinar cells via angiotensin-converting enzyme 2 and neurophilin-1 (NRP1), causing pancreatic &#946;-cell dysfunction [<xref rid="B63-biology-11-01662" ref-type="bibr">63</xref>,<xref rid="B64-biology-11-01662" ref-type="bibr">64</xref>]. In fact, viral replication and apoptosis have been observed in pancreatic &#946;-cells infected with SARS-CoV-2 [<xref rid="B64-biology-11-01662" ref-type="bibr">64</xref>,<xref rid="B65-biology-11-01662" ref-type="bibr">65</xref>,<xref rid="B66-biology-11-01662" ref-type="bibr">66</xref>,<xref rid="B67-biology-11-01662" ref-type="bibr">67</xref>]. Alternatively, upon SARS-CoV-2 infection, pancreatic &#946;-cells show low insulin expression, high glucagon expression, and high trypsin 1 expression, suggesting transdifferentiating of pancreatic &#946;-cells [<xref rid="B64-biology-11-01662" ref-type="bibr">64</xref>,<xref rid="B68-biology-11-01662" ref-type="bibr">68</xref>]. These facts suggest the possibility of pancreatic &#946;-cell dysfunction caused by SARS-CoV-2 leading to virus-induced diabetes [<xref rid="B68-biology-11-01662" ref-type="bibr">68</xref>]. If an individual before the onset of AT1D or type 2 diabetes suffers from COVID-19, pancreatic &#946; -cell damage may accelerate the onset of diabetes. This assumption is consistent with the results of epidemiological studies showing an increased risk of developing diabetes mellitus in those with COVID-19 [<xref rid="B69-biology-11-01662" ref-type="bibr">69</xref>]. </p><p>Some patients who develop diabetes in the process of COVID-19 also improve their diabetes with the improvement of COVID-19 [<xref rid="B70-biology-11-01662" ref-type="bibr">70</xref>]. In such cases, inflammation, cytokines, antivirals, and steroid therapy are considered to have caused hyperglycemia, in addition to transient viral cell damage [<xref rid="B71-biology-11-01662" ref-type="bibr">71</xref>,<xref rid="B72-biology-11-01662" ref-type="bibr">72</xref>,<xref rid="B73-biology-11-01662" ref-type="bibr">73</xref>,<xref rid="B74-biology-11-01662" ref-type="bibr">74</xref>,<xref rid="B75-biology-11-01662" ref-type="bibr">75</xref>]. </p><p>Interestingly, SARS-CoV-2 has also been shown to infect macrophages via ACE or CD16. Infection of macrophages by SARS-CoV-2 activates inflammasomes and drives pyroptosis. Pyroptosis interrupts the viral replication cycle but releases immune cell activators and triggers a hyper-inflammatory state by other macrophages [<xref rid="B76-biology-11-01662" ref-type="bibr">76</xref>]. This hyper-inflammatory state is supposed to be involved in the exacerbation of COVID-19, but it is unknown whether it is involved in the development of diabetes. Importantly, there is a lack of evidence that SARS-CoV-2 infection initiates immune disorders leading to AT1D or FT1D.</p><p>There are mixed epidemiological reports of the association between COVID-19 and the development of T1D. Although some regions have reported increased incidences of T1D after the spread of COVID-19, others did not report this association; therefore, there is a lack of consensus in this regard [<xref rid="B77-biology-11-01662" ref-type="bibr">77</xref>,<xref rid="B78-biology-11-01662" ref-type="bibr">78</xref>]. Recent real-world data indicates COVID-19 diagnosis is associated with increased risk of new-onset T1D in American Indian and Alaskan Native peoples, Asian and Pacific Islander peoples, Black populations, infants, and the elderly [<xref rid="B79-biology-11-01662" ref-type="bibr">79</xref>].</p><p>In areas with strict lockdown and other infection control measures, there has been a decrease in the incidence of common viral infections, such as enterovirus infections, which may even lead to fewer T1D patients in the future [<xref rid="B78-biology-11-01662" ref-type="bibr">78</xref>]. Therefore, this trend may vary depending on regional characteristics, race, and age, and requires further investigation. </p><p>During the pandemic, the frequency and severity of DKA in newly diagnosed T1D patients were higher than before [<xref rid="B80-biology-11-01662" ref-type="bibr">80</xref>,<xref rid="B81-biology-11-01662" ref-type="bibr">81</xref>,<xref rid="B82-biology-11-01662" ref-type="bibr">82</xref>]. It is important to investigate whether these severe cases mean FT1D or not. However, according to the details of many case reports, most cases have not met the Japanese diagnostic criteria for FT1D because of the high value of HbA1c or the individual is positive for GADAb. Most of the newly diagnosed T1D patients in these epidemiological studies were negative for SARS-CoV-2 at the onset [<xref rid="B83-biology-11-01662" ref-type="bibr">83</xref>,<xref rid="B84-biology-11-01662" ref-type="bibr">84</xref>]. Furthermore, no case of FT1D or increase in FT1D incidence has been confirmed, even in Japan. Therefore, as these epidemiological studies conclude, delays in medical access attributable to the lockdown or fear of infection may have caused delays in the treatment of new-onset AT1D, leading to DKA [<xref rid="B85-biology-11-01662" ref-type="bibr">85</xref>,<xref rid="B86-biology-11-01662" ref-type="bibr">86</xref>]. Currently, there is little evidence of a causal link between SARS-CoV-2 and FT1D, but during this pandemic, it is important to pay attention to the rapidity of the diabetic clinical course in patients with relatively low HbA1c levels at diagnosis so as not to overlook FT1D.</p><p>To protect from the severe pandemic of COVID-19, various anti-COVID-19 vaccines have been developed [<xref rid="B87-biology-11-01662" ref-type="bibr">87</xref>] and approximately 60% of the world&#8217;s population has received at least one dose of vaccination (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ourworldindata.org/covid-vaccinations">https://ourworldindata.org/covid-vaccinations</uri> Coronavirus (COVID-19) Vaccinations&#8212;Our World in Data, accessed on 2 November 2022). </p><p>Recently, case reports of FT1D occurring after COVID-19 vaccination are arriving from mainly East Asia. At this time, what these reports have in common is that the patients had risk factors for FT1D, such as disease susceptible HLA alleles or a past history of use of immune checkpoint inhibitors [<xref rid="B88-biology-11-01662" ref-type="bibr">88</xref>,<xref rid="B89-biology-11-01662" ref-type="bibr">89</xref>,<xref rid="B90-biology-11-01662" ref-type="bibr">90</xref>]. Therefore, these reports caution clinicians that FT1D might develop after COVID-19 vaccination in individuals with susceptible backgrounds. </p><p>The long history of vaccines has shown that the immune-stimulatory properties of vaccines can trigger immune disorders including autoimmune diseases [<xref rid="B91-biology-11-01662" ref-type="bibr">91</xref>,<xref rid="B92-biology-11-01662" ref-type="bibr">92</xref>]. In addition, molecular mimicry between the SARS-CoV-2 spike (S) protein and human endocrine cells, including pancreatic &#946;-cells, has been pointed out. In fact, both widely used mRNA and adenovirus vector-based vaccines encode the S protein, which is targeted by neutralizing antibodies [<xref rid="B87-biology-11-01662" ref-type="bibr">87</xref>,<xref rid="B93-biology-11-01662" ref-type="bibr">93</xref>]. Therefore, we cannot exclude the possibility that vaccine-induced immune activation and molecular mimicry might be involved in the development of FT1D. On the one hand, it is also possible that the timing of vaccination and FT1D onset coincided by chance. Therefore, accumulation of further cases is necessary to clarify the causal relationship between the vaccination and the development of T1D. </p></sec><sec id="sec4dot5-biology-11-01662"><title>4.5. Mouse Diabetes Model Induced by Encephalomyocarditis Virus (EMCV)</title><p>Like enterovirus, EMCV belongs to the Picornaviridae family. EMCV is the most thoroughly studied diabetes-associated virus in mice and much evidence has been accumulated via a mouse model that rapidly develops diabetes [<xref rid="B94-biology-11-01662" ref-type="bibr">94</xref>]. Since the concept of human FT1D was reported, attention has been focused on the similarities between this model and FT1D [<xref rid="B95-biology-11-01662" ref-type="bibr">95</xref>].</p><p>First, it was reported that the injected EMC M variant (EMC-M) virus induces diabetes as a result of pancreatic &#946;-cell infection, but the onset was inconsistent. Therefore, EMC-M viral plaque purification was performed to isolate two mutants: diabetes-induced EMC-D virus and a non-diabetes EMC-B virus [<xref rid="B96-biology-11-01662" ref-type="bibr">96</xref>]. </p><p>Although EMC-D differs from the B variant (EMC-B) by only a few nucleotide bases, EMC-B does not cause diabetes, suggesting that naturally occurring genetic mutations in a virus can alter its capacity to induce diabetes. Sensitivity to EMCV is affected by age, gender, and genetic factors. As a genetic factor, susceptibility varies depending on the mouse strain: SJL/J and DBA/2 are sensitive, while C57B/6 is resistant [<xref rid="B96-biology-11-01662" ref-type="bibr">96</xref>]. </p><p>In sensitive mice, EMC infection causes severe inflammatory cell infiltration into islets, and the inflammation extends to the exocrine pancreatic region. The inflammatory cells mainly comprise of macrophages, and the peak timepoint is 72 to 120 h after infection [<xref rid="B97-biology-11-01662" ref-type="bibr">97</xref>]. Severe pancreatic &#946;-cell lysis is caused by extreme &#8220;high-dose&#8221; virus injections, which are unlikely to occur in nature [<xref rid="B98-biology-11-01662" ref-type="bibr">98</xref>].</p><p>Simultaneously, there is a transient increase in insulin levels and a decrease in blood glucose levels, which are signs of rapid pancreatic &#946;-cell destruction, followed by the rapid disappearance of insulin and the appearance of hyperglycemia [<xref rid="B95-biology-11-01662" ref-type="bibr">95</xref>]. The inflammation disappears within a few days, but the pancreatic &#946;-cells are destroyed, making it difficult for the mice to survive without insulin. This time course is similar to that of FT1D. </p><p>Sensitive SJL/J mice are known to have mutations in the tyrosine kinase 2 (<italic toggle="yes">Tyk2</italic>) gene associated with the capacity of interferon-dependent defense, an important part of innate immunity against viral infections [<xref rid="B99-biology-11-01662" ref-type="bibr">99</xref>]. Introducing this mutation into disease-resistant C57B/6 mice leads to the development of diabetes by EMCV, suggesting that the <italic toggle="yes">Tyk2</italic> mutation is associated with disease sensitivity in mice. Partial dysfunction of innate immunity due to this mutation could lead to an increased viral load [<xref rid="B99-biology-11-01662" ref-type="bibr">99</xref>]. Activating innate immunity with the administration of <italic toggle="yes">Corynebacterium parvum</italic> before EMCV infection can halt the onset of diabetes, demonstrating the importance of early antiviral action in preventing diabetes development [<xref rid="B100-biology-11-01662" ref-type="bibr">100</xref>]. Experiments with T cell or B cell-deficient mice have shown no protective or promoting effect on diabetes, but macrophage inactivation prior to viral infection prevents diabetes.</p><p>Upon low-dose infection of mice, the virus initially replicates in pancreatic &#946;-cells, leading to the recruitment of macrophages that are activated at the pancreatic islets. These activated macrophages produce interleukin-1 &#946; (IL-1 &#946;), tumor necrosis factor-&#945; (TNF-&#945;), and nitric oxide (NO), which induces the destruction of pancreatic &#946;-cells [<xref rid="B101-biology-11-01662" ref-type="bibr">101</xref>]. These results indicate that viral pancreatic &#946;-cell lysis and innate immune disorders, such as reduced initial viral clearance and overactivation of macrophages, play major roles in the pathophysiology of fulminant diabetes in the mouse model. </p></sec><sec id="sec4dot6-biology-11-01662"><title>4.6. Pregnancy-Related FT1D (PF)</title><p>Reportedly, FT1D tends to occur from the third trimester of pregnancy to immediately after delivery [<xref rid="B102-biology-11-01662" ref-type="bibr">102</xref>]. In women of reproductive age (13&#8211;49 years old), FT1D that is unrelated to pregnancy is distinguished from PF as non-pregnancy-related FT1D (NPF). </p><p>In a nationwide survey by the Japan Diabetes Society, PF accounted for 21% of FT1D patients in women aged 13&#8211;49 years, and most of the patients who developed T1D during pregnancy had FT1D [<xref rid="B102-biology-11-01662" ref-type="bibr">102</xref>]. The third trimester of pregnancy overlaps with a period of increased insulin resistance, and thus, the severity of DKA is higher than that in NPF, along with a stillbirth or miscarriage rate of 63.6% [<xref rid="B102-biology-11-01662" ref-type="bibr">102</xref>]. </p><p>Despite immune tolerance during pregnancy, PF can develop not only after delivery but also during pregnancy; thus, the similarities and differences between FT1D before and after delivery need to be studied. </p><p>HLA susceptibility also differs between PF and NPF, with <italic toggle="yes">DRB*09:01-DQB1*03:03</italic> (DR9) haplotypes observed more frequently in PF than in NPF [<xref rid="B103-biology-11-01662" ref-type="bibr">103</xref>] and <italic toggle="yes">DRB1*04:05-DQB1*04:01</italic>, the most common haplotype in FT1D, observed more frequently in NPF than in PF of Japanese patients [<xref rid="B103-biology-11-01662" ref-type="bibr">103</xref>]. There is no difference in the frequency of flu-like symptoms between PF and NPF (both about 70%) [<xref rid="B103-biology-11-01662" ref-type="bibr">103</xref>]. Thus, the involvement of viral infections is suspected in both cases; however, this phenomenon has only been verified in a small number of cases and requires further validation. </p></sec><sec id="sec4dot7-biology-11-01662"><title>4.7. Immune Checkpoint Inhibitor (ICI)-Related FT1D</title><p>Recently, ICIs such as anti-programmed cell death protein 1 (PD-1) antibodies, anti- programmed cell death ligand 1 (PD-L1) antibodies, and anti-CTLA-4 antibodies have contributed greatly to cancer therapy and have improved the prognosis of advanced cancer patients. In addition, immune checkpoints are crucial for self-tolerance and immune-related adverse events (irAEs) induced by ICIs are concerning. In irAEs, endocrine disorders, enteritis, hepatitis, and interstitial pneumonia are relatively common, and each frequency is over 5&#8211;10%, which is at a warning level [<xref rid="B12-biology-11-01662" ref-type="bibr">12</xref>]. T1D is also one of the irAEs and the frequency is rare at approximately 0.1&#8211;2.2% [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>,<xref rid="B105-biology-11-01662" ref-type="bibr">105</xref>,<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>]. However, precaution is necessary because ICI-related T1D patients require permanent insulin therapy to protect their lives, and certain ICI-related T1D are fatal if treatment is not initiated shortly after onset [<xref rid="B105-biology-11-01662" ref-type="bibr">105</xref>]. There is no exception in Caucasians, where the FT1D was considered rare. In fact, with the widespread use of ICIs, reports of ICI-related FT1D in Caucasians are increasing [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>,<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>,<xref rid="B107-biology-11-01662" ref-type="bibr">107</xref>].</p><p>In recent years, cases of ICI-related diabetes have been reported from various countries, and analysis of these reports is gradually revealing the entity of ICI-related diabetes. As an overview based on some reviews, the average age of onset of ICI-related diabetes is in the 60s, consistent with the cancer-prone age, which is higher than that of classic T1D [<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>,<xref rid="B107-biology-11-01662" ref-type="bibr">107</xref>,<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>,<xref rid="B109-biology-11-01662" ref-type="bibr">109</xref>]. Males account for 50&#8211;60% patients, slightly more than females, reflecting that the populations treated with ICIs are most commonly used for melanoma and non-small cell lung cancer [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>,<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>,<xref rid="B107-biology-11-01662" ref-type="bibr">107</xref>,<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>,<xref rid="B109-biology-11-01662" ref-type="bibr">109</xref>]. The onset varies from 13 to 504 days after the initial dose of ICI, sometimes even after the first dose, up to more than one year after initiation of ICI, but the mean or median is four months or four cycles later [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>,<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>,<xref rid="B107-biology-11-01662" ref-type="bibr">107</xref>,<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>,<xref rid="B109-biology-11-01662" ref-type="bibr">109</xref>,<xref rid="B110-biology-11-01662" ref-type="bibr">110</xref>,<xref rid="B111-biology-11-01662" ref-type="bibr">111</xref>]. </p><p>DKA is a common presentation for ICI-related T1D, with the incidence varying from 39&#8211;68% based on some reviews [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>]. According to a European report, the frequency of DKA in T1D is 21%, and conventional FT1D usually develops DKA. Therefore, its frequency is intermediate between classic T1D and conventional FT1D [<xref rid="B112-biology-11-01662" ref-type="bibr">112</xref>].</p><p>The C-peptide level of ICI-related T1D is usually low or undetectable, but it has also been reported that sometimes C-peptide levels recover slightly after the end of ICI therapy [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>]. This is an intermediate feature between classic T1D, in which C-peptide is detected for a relatively longer period of time after onset, and conventional FT1D, in which C-peptide is depleted at the onset. The average or median blood glucose level at the diagnosis of ICI-related T1D is 560&#8211;650 mg/dl, which is higher than that of 434 mg/dl in Japanese acute-onset T1D and 385 mg/dl in Caucasian acute-onset T1D, and lower than 853 mg/dl of Japanese FT1D [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>]. These facts suggest that the rapidity of pancreatic &#946;-cell destruction is faster than acute-onset T1D and slower than conventional FT1D. The mean HbA1c at the onset of ICA-related diabetes is 7.9% [<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>], which is lower than that of T1D, approximately 9% [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>,<xref rid="B113-biology-11-01662" ref-type="bibr">113</xref>], and this relatively low HbA1c level also suggests faster progression than acute onset type 1 diabetes and resembles conventional FT1D.</p><p>In contrast to patients with acute-onset T1D, of whom more than 80% have islet-related autoantibodies, the positive rate in ICI related T1D patients is only approximately 50% [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>,<xref rid="B114-biology-11-01662" ref-type="bibr">114</xref>]. Thus, relatively numerous patients belong to idiopathic T1D, clearly distinguishing it from AT1D. Especially, the positive patients are rare in Japanese people [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>], so it is expected to vary by race [<xref rid="B106-biology-11-01662" ref-type="bibr">106</xref>,<xref rid="B107-biology-11-01662" ref-type="bibr">107</xref>]. In patients wherein the HLA haplotype was investigated, 51.3% showed the DR4 and 14.1% the DR9 phenotype, while in 10.3%, protective phenotypes for T1D (DR7, DR11, or DR15) were detected [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>]. The median blood glucose level at the onset in patients with HLA-DR4 was higher than in non-DR4 HLA patients, and the onset of patients with the T1D protective HLA-DR was later than the others [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>]. </p><p>At the onset of FT1D, the elevation of pancreatic exocrine enzyme has been reported in most patients, and some patients were accompanied with pancreatic swelling or acute pancreatitis, supporting the possibility of rapid islet and exocrine injury [<xref rid="B115-biology-11-01662" ref-type="bibr">115</xref>]. Moreover, ICI-related T1D varies from FT1D-like with pancreatitis to classical T1D-like with mild or no pancreatic enzyme elevation. In addition, if elevated pancreatic enzymes are observed at the time of the diagnosis of classic T1D, it may be a nonspecific change based on DKA [<xref rid="B116-biology-11-01662" ref-type="bibr">116</xref>]. In a recent meta-analysis, 51% of patients diagnosed with ICI related T1D had an increase in either lipase and/or amylase at diagnosis, and the frequency is disproportionately higher than that of classic T1D [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>]. </p><p>Recently, the concept of AT1D as a combined endocrine&#8211;exocrine disease has become commonplace because it has become clear that inflammatory cell infiltration, fibrosis, and acinar cell depletion in exocrine glandular tissue are simultaneously advanced [<xref rid="B117-biology-11-01662" ref-type="bibr">117</xref>]. A decrease in insulin action on acinar cells is considered to be one of the factors of exocrine atrophy, but in preclinical ATID and even in slowly progressive type 1 insulin-dependent diabetes mellitus (SPIDDM)/ latent autoimmune diabetes in adults (LADA) whose insulin secretion is relatively maintained, morphological changes in the exocrine glands have been observed. Therefore, it is assumed that important immune mechanisms that affect exocrine tissue exist in T1D, and it is also necessary to investigate whether this mechanism, and that of pancreatitis in FT1D and ICI-related T1D, are on the same spectrum.</p><p>From these facts, it can be stated that ICI-related T1D has various phenotypes, from FT1D to AT1D. In fact, it has been reported that approximately 40&#8211;50% of ICI-related diabetes meet the Japanese diagnostic criteria for FT1D [<xref rid="B104-biology-11-01662" ref-type="bibr">104</xref>]. So, it is also important to focus on the difference between conventional FT1D and ICI-related FT1D. Unlike conventional FT1D, flu-like symptoms are rare in ICI-related diabetes and are rarely reported to be associated with viral infection. Therefore, the direct association between ICI-related FT1D and viruses may be less than that of conventional FT1D.</p><p>ICI-related diabetes was primarily caused by PD-1 or PDL1 antibodies and was rarely caused by CTLA4 antibodies. The role of immune checkpoints in T1D has been investigated in mice and humans. Non-obese diabetic (NOD) mice rapidly develop diabetes following the experimental blockade of PD-1 or PD-L1 [<xref rid="B113-biology-11-01662" ref-type="bibr">113</xref>,<xref rid="B118-biology-11-01662" ref-type="bibr">118</xref>]. This corresponds with the finding that pancreatic islets express PD-L1 at low levels in mice and are more upregulated in inflamed islets [<xref rid="B119-biology-11-01662" ref-type="bibr">119</xref>,<xref rid="B120-biology-11-01662" ref-type="bibr">120</xref>]. In humans, polymorphisms in the PD-1 gene confer increased susceptibility to a variety of autoimmune disorders, including T1D [<xref rid="B121-biology-11-01662" ref-type="bibr">121</xref>,<xref rid="B122-biology-11-01662" ref-type="bibr">122</xref>,<xref rid="B123-biology-11-01662" ref-type="bibr">123</xref>]. Therefore, viral infection is considered to trigger conventional fulminant type 1 diabetes, while inhibition of PD-1 or PD-L1 is thought to trigger ICI-related FT1D. </p><p>Based on the above evidence, ICIs are triggers of FT1D in addition to viruses, but it may be appropriate to understand ICI-related diabetes, including ICI-related FT1D, as an independent and a novel category from an etiological approach [<xref rid="B108-biology-11-01662" ref-type="bibr">108</xref>] (<xref rid="biology-11-01662-f001" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec id="sec5-biology-11-01662"><title>5. Immune Mechanism</title><sec id="sec5dot1-biology-11-01662"><title>5.1. Innate Immunity and FT1D</title><p>The characteristic clinical course of FT1D, that is, onset following flu-like symptoms and rapidity, suggests that innate immunity plays an important role in disease pathogenesis. The innate immune response to viruses involves the natural killer (NK) cell-mediated clearance of virus-infected cells, phagocytosis by macrophages, and suppression of viral proliferation by interferons (IFNs) produced by inflammatory and infected cells. Of the molecules that recognize pathogens, important pattern recognition receptors with a lower level of specificity include macrophage toll-like receptors (TLRs) and the intracellular viral receptors, namely retinoic acid-inducible protein-1 (RIG-I) and melanoma differentiation-associated protein-5 (MDA-5). </p><p>The immunopathology of FT1D is challenging to study in humans because of the extremely rapid clinical course, but some reports revealed the details using pancreas samples removed from patients who died shortly after the onset of FT1D. Tanaka et al. studied autopsied pancreata from three patients and reported prominent infiltration of macrophages, cytotoxic T cells, and dendritic cells into the islets and exocrine region, along with the presence of enterovirus VP1 antigens in the pancreatic islets and exocrine region [<xref rid="B124-biology-11-01662" ref-type="bibr">124</xref>]. Furthermore, Aida et al. reported increased expression of the intracellular viral receptors RIG-I and MDA-5 in islet cells and increased expression of IFN-&#945;/&#946;, IFN-&#947;, CXCL-10, and FAS in pancreatic &#946;-cells [<xref rid="B125-biology-11-01662" ref-type="bibr">125</xref>]. </p><p>Our analysis of autopsied pancreatic tissue from three patients that died immediately after FT1D onset revealed infiltration of macrophages in 96.2% and T cells in 68.8% of the islets and TLR-3, -7, and -9 expression in most islet cells. Additionally, the study revealed depleted pancreatic &#946;- and &#945;-cells [<xref rid="B2-biology-11-01662" ref-type="bibr">2</xref>]. Furthermore, in situ hybridization confirmed the presence of enteroviral RNA in islets with remnant pancreatic &#946;-cells in one of the three patients [<xref rid="B2-biology-11-01662" ref-type="bibr">2</xref>]. Nishida et al. carried out proteomic analysis of islets in autopsy samples obtained from patients with FT1D and detected new proteins associated with cell migration (lymphocyte cytosolic protein 1), virus replication (adenosine triphosphate-dependent RNA helicase, DEAD box helicase 5), and antiviral activity (SAM domain and HD domain-containing protein 1) [<xref rid="B126-biology-11-01662" ref-type="bibr">126</xref>]. These findings support the hypothesis that viral infection of pancreatic islet cells could induce infiltration of immune cells to the islets, resulting in pancreatic &#946;-cell destruction through immune reactions to the virus, but there is insufficient evidence to explain the rapid and complete mechanism underlying pancreatic &#946;-cell destruction. </p><p>Experiments in EMCV-resistant C57/B6 mice demonstrated that a deficiency of MDA-5 or TLR-3 leads to the development of diabetes, suggesting that attenuated activity of these molecules, especially TLR3, may lead to blunted type1 IFN response, uncontrolled virus replication, and diabetes during pancreatic &#946;-cell tropic virus infection [<xref rid="B127-biology-11-01662" ref-type="bibr">127</xref>].</p><p>Some studies suggest that NK cell dysfunction is involved in impaired innate immunity in FT1D patients. Analysis of peripheral blood from FT1D patients revealed that the expression of killer cell lectin-like receptor subfamily C3 (KLRC3) and CD94 that form activated receptors on NK cells, as well as the proportion of NK cells in the peripheral blood mononuclear cells, was lower in FT1D than in healthy subjects [<xref rid="B128-biology-11-01662" ref-type="bibr">128</xref>]. In a similar report, the genetic analysis of peripheral blood mononuclear cells in FT1D patients showed upregulation of interleukin-1 accessory receptor protein (IL1RAP) and downregulation of TLR-9 and the transcription factor ELF4, suggesting a decline in NK cell function. In fact, the NK activity measured by Methyl thiazoleterazolium (MTT) assay was reduced in FT1D patients. [<xref rid="B129-biology-11-01662" ref-type="bibr">129</xref>]. These results provide a hypothesis that the failure of NK cell activation leads to the loss of the ability to eliminate the causative virus. This failure of initial virus elimination is an interesting phenomenon that was also confirmed in EMC model mice; and should be noteworthy in the investigation of FT1D pathogenesis. However, it is unclear whether this phenomenon leads to excessive immune responses by macrophages or cytotoxic T cells.</p></sec><sec id="sec5dot2-biology-11-01662"><title>5.2. Acquired Immunity and FT1D</title><p>While aberrant innate immunity is considered to be the primary etiology of FT1D, the rapid and particularly complete depletion of pancreatic &#946;-cells suggests the involvement of other factors such as acquired immunity. In addition, the fact that <italic toggle="yes">DRB1*04:05-DQB1*04:01</italic> and <italic toggle="yes">DRB1*09:01-DQB1*03:03</italic> were associated not only with AT1D but also FT1D in Japan raises debate about the involvement of autoimmunity in FT1D.</p><p>Secreted CXCL10 activates and recruits not only macrophages but also T cells via CXCR3. This common phenomenon has also been confirmed in AT1D [<xref rid="B130-biology-11-01662" ref-type="bibr">130</xref>]. Overexpression of the interferon-induced chemokine CXCL10 by enteroviral infection of pancreatic islet cells has been proposed as an early molecular marker of infection [<xref rid="B131-biology-11-01662" ref-type="bibr">131</xref>]. In FT1D, the serum levels of CXCL10 were increased at the onset [<xref rid="B132-biology-11-01662" ref-type="bibr">132</xref>]; furthermore, the expression of CXCL10 in pancreatic islets and the accumulation of CXCR3-positive T cells have been confirmed in the autopsy pancreata of three patients [<xref rid="B133-biology-11-01662" ref-type="bibr">133</xref>]. Therefore, it is hypothesized that antiviral and/or autoreactive T cells are also involved in the destruction of pancreatic &#946;-cells.</p><p>As mentioned previously, GADAb were detected in approximately 5% of FT1D patients, whereas either islet-related autoantibodies were detected in approximately 18% of FT1D patients [<xref rid="B134-biology-11-01662" ref-type="bibr">134</xref>]. Some FT1D patients negative for GADAb at onset have been observed to become positive over the course of the disease [<xref rid="B135-biology-11-01662" ref-type="bibr">135</xref>]. In addition, T cells reacting with islet components [<xref rid="B136-biology-11-01662" ref-type="bibr">136</xref>], amylase &#945;2 antibodies, and HSP10 antibodies have been detected in the peripheral blood of FT1D patients [<xref rid="B13-biology-11-01662" ref-type="bibr">13</xref>,<xref rid="B14-biology-11-01662" ref-type="bibr">14</xref>], suggesting the involvement of autoimmunity. Tada et al. created CD28-knockout non-obese diabetic (NOD) mice with significantly fewer regulatory T cells and found that insulitis occurred earlier in CD28-knockout than in ordinary NOD mice. They also reported that the administration of poly (I:C) in the mice simulated a viral infection and immediately led to islet destruction, similar to its occurrence in FT1D [<xref rid="B137-biology-11-01662" ref-type="bibr">137</xref>]. In humans, an analysis of the expression of CTLA4 in the peripheral blood T cells of FT1D patients revealed reduced expression of both regulatory T cells and effector T cells, as well as reduced suppression of the proliferation of effector T cells [<xref rid="B138-biology-11-01662" ref-type="bibr">138</xref>,<xref rid="B139-biology-11-01662" ref-type="bibr">139</xref>]. The reduced inhibitory functions of regulatory T cells indicate that FT1D is characterized by an excessive immune response by cytotoxic T cells to virus-infected islet cells. </p><p>These findings indicate that the development of FT1D is associated with aberrant innate immunity as well as impaired regulatory T cell function, which is considered to trigger an exaggerated adaptive immune response against virus and self-antigens, leading to rapid and complete destruction of pancreatic &#946;-cells (<xref rid="biology-11-01662-f002" ref-type="fig">Figure 2</xref>). </p></sec></sec><sec sec-type="conclusions" id="sec6-biology-11-01662"><title>6. Conclusions</title><p>In this review, we have outlined the features of FT1D and the role of viruses in FT1D pathophysiology. Diagnosing FT1D without delay is essential to reduce the risk of sudden death.</p><p>Patients with FT1D sometimes visit the hospital complaining of severe fatigue following the symptoms of the common cold. If clinicians encounter such cases, it is necessary to ask in detail whether the patient has symptoms of sudden hyperglycemia such as thirst, polydipsia, and polyuria. Additionally, in such cases, urinalysis will be of great help. If urinary sugar and urinary ketone bodies are detected, FT1D is strongly suspected, and blood glucose levels should be measured immediately. </p><p>When conducting an epidemiological study of acute-onset T1D associated with COVID-19, HbA1c at the onset should be focused on. If the HbA1c is less than 8.7%, there is a possibility of FT1D. In addition, the rapid clinical course and low C-peptide levels strongly support the existence of FT1D.</p><p>Currently, there is little evidence of an increase in the number of cases of FT1D after SARS-CoV-2 infection. However, it is possible that FT1D was hidden behind the sudden death after COVID-19. Alternatively, FT1D may have been included in diabetes that develops during the course of COVID-19. Therefore, it is necessary to raise global awareness of FT1D and carefully monitor the relationship between FT1D and COVID-19.</p><p>Finally, it is also necessary to pay attention to how the temporal high-hygiene environment, owing to measures against COVID-19, will affect T1D and viral infections in the future.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>H.S.&#8212;writing review and editing; A.I.&#8212;writing review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biology-11-01662"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyagawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matsuzawa</surname><given-names>Y.</given-names></name><collab>for the Osaka IDDM Study Group</collab></person-group><article-title>A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1056/NEJM200002033420501</pub-id><pub-id pub-id-type="pmid">10655528</pub-id></element-citation></ref><ref id="B2-biology-11-01662"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tauriainen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oikarinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abiru</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takase</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Expression of Toll-Like Receptors in the Pancreas of Recent-Onset Fulminant type 1 Diabetes</article-title><source>Endocr. J.</source><year>2010</year><volume>57</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K09E-291</pub-id><pub-id pub-id-type="pmid">20009359</pub-id></element-citation></ref><ref id="B3-biology-11-01662"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanatsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Fulminant type 1 Diabetes: A Nationwide Survey in Japan</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>2345</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.8.2345</pub-id><pub-id pub-id-type="pmid">12882860</pub-id></element-citation></ref><ref id="B4-biology-11-01662"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name></person-group><article-title>Fulminant type 1 diabetes in Korea: High prevalence among patients with adult-onset type 1 diabetes</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>2276</fpage><lpage>2279</lpage><pub-id pub-id-type="doi">10.1007/s00125-007-0812-z</pub-id><pub-id pub-id-type="pmid">17724575</pub-id></element-citation></ref><ref id="B5-biology-11-01662"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name></person-group><article-title>Clinical analysis of fulminant type 1 diabetes in China and comparison with a nationwide survey in Japan</article-title><source>Ann. Endocrinol.</source><year>2013</year><volume>74</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ando.2012.11.006</pub-id><pub-id pub-id-type="pmid">23357571</pub-id></element-citation></ref><ref id="B6-biology-11-01662"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Konoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fujiyama</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Differences in the contribution of HLA-DR and -DQ haplotypes to susceptibility to adult-onset and childhood-onset type 1 diabetes in Japanese patients</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>2684</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.10.2684</pub-id><pub-id pub-id-type="pmid">15448101</pub-id></element-citation></ref><ref id="B7-biology-11-01662"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>Fulminant Type 1 Diabetes Mellitus: A New Class of Type 1 Diabetes</article-title><source>Adv. Exp. Med. Biol.</source><year>2012</year><volume>771</volume><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-5441-0_3</pub-id><pub-id pub-id-type="pmid">23393667</pub-id></element-citation></ref><ref id="B8-biology-11-01662"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>Fulminant Type 1 Diabetes Mellitus</article-title><source>Endocr. J.</source><year>2006</year><volume>53</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1507/endocrj.KR-72</pub-id><pub-id pub-id-type="pmid">16873987</pub-id></element-citation></ref><ref id="B9-biology-11-01662"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>N.</given-names></name><name name-style="western"><surname>Motokura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Rapid Loss of Insulin Secretion in a Patient with Fulminant Type 1 Diabetes Mellitus and Carbamazepine Hypersensitivity Syndrome</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>1153</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1001/jama.285.9.1153</pub-id><pub-id pub-id-type="pmid">11231743</pub-id></element-citation></ref><ref id="B10-biology-11-01662"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kimata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Imbe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shibasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Case of Fulminant Type 1 Diabetes Patient Accompanied by Hyperinsulinemic Hypoglycemia Prior to Clinical Diagnosis of Diabetes</article-title><source>J. Jpn. Diabetes Soc.</source><year>2016</year><volume>59</volume><fpage>210</fpage><lpage>217</lpage></element-citation></ref><ref id="B11-biology-11-01662"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Awata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikegami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Osawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-Onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus</article-title><source>J. Diabetes Investig.</source><year>2012</year><volume>3</volume><fpage>536</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/jdi.12024</pub-id><pub-id pub-id-type="pmid">24843620</pub-id><pub-id pub-id-type="pmcid">PMC4015434</pub-id></element-citation></ref><ref id="B12-biology-11-01662"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albandar</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Fuqua</surname><given-names>J.</given-names></name><name name-style="western"><surname>Albandar</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Safi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>P.C.</given-names></name></person-group><article-title>Immune-Related Adverse Events (IrAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>989</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13050989</pub-id><pub-id pub-id-type="pmid">33673446</pub-id><pub-id pub-id-type="pmcid">PMC7956829</pub-id></element-citation></ref><ref id="B13-biology-11-01662"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takizawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kamisawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group><article-title>Amylase alpha-2A Autoantibodies: Novel Marker of Autoimmune Pancreatitis and Fulminant type 1 Diabetes</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>732</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.2337/db08-0493</pub-id><pub-id pub-id-type="pmid">19001184</pub-id><pub-id pub-id-type="pmcid">PMC2646073</pub-id></element-citation></ref><ref id="B14-biology-11-01662"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takizawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wanjia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group><article-title>HSP 10 Is a New Autoantigen in Both Autoimmune Pancreatitis and Fulminant type 1 Diabetes</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2009</year><volume>386</volume><fpage>192</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.06.009</pub-id><pub-id pub-id-type="pmid">19520060</pub-id></element-citation></ref><ref id="B15-biology-11-01662"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haseda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mitsui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murase-Mishiba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160576</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160576</pub-id><pub-id pub-id-type="pmid">27513516</pub-id><pub-id pub-id-type="pmcid">PMC4981355</pub-id></element-citation></ref><ref id="B16-biology-11-01662"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oram</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Besser</surname><given-names>R.E.J.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hattersley</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>T.J.</given-names></name></person-group><article-title>Erratum to: The Majority of Patients with Long-Duration Type 1 Diabetes Are Insulin Microsecretors and have Functioning Beta Cells</article-title><source>Diabetologia</source><year>2014</year><volume>57</volume><fpage>262</fpage><pub-id pub-id-type="doi">10.1007/s00125-013-3103-x</pub-id><pub-id pub-id-type="pmcid">PMC3855529</pub-id><pub-id pub-id-type="pmid">24121625</pub-id></element-citation></ref><ref id="B17-biology-11-01662"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Infante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ricordi</surname><given-names>C.</given-names></name></person-group><article-title>Editorial&#8212;Moving Forward on the Pathway of Targeted Immunotherapies for Type 1 Diabetes: The Importance of Disease Heterogeneity</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2019</year><volume>23</volume><fpage>8702</fpage><lpage>8704</lpage><pub-id pub-id-type="pmid">31646605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201910_19188</pub-id></element-citation></ref><ref id="B18-biology-11-01662"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murase</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanatsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Fulminant Type 1 Diabetes as a High Risk Group for Diabetic Microangiopathy&#8212;A Nationwide 5-Year-Study in Japan</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0575-y</pub-id><pub-id pub-id-type="pmid">17235525</pub-id></element-citation></ref><ref id="B19-biology-11-01662"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaike</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakagami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>Y.</given-names></name></person-group><article-title>Incidence and Development of Diabetic Microangiopathy of Fulminant Type 1 Diabetes&#8212;Comparison with Non-Fulminant Type 1 Diabetes</article-title><source>Intern. Med.</source><year>2010</year><volume>49</volume><fpage>1079</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.49.3294</pub-id><pub-id pub-id-type="pmid">20558921</pub-id></element-citation></ref><ref id="B20-biology-11-01662"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ciesielska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kucza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurczewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ku&#378;mi&#324;ska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma&#263;kowiak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niechcia&#322;</surname><given-names>E.</given-names></name></person-group><article-title>Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>2805</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9092805</pub-id><pub-id pub-id-type="pmid">32872668</pub-id><pub-id pub-id-type="pmcid">PMC7563637</pub-id></element-citation></ref><ref id="B21-biology-11-01662"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougn&#232;res</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Landais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boisson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carel</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Frament</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boitard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chaussain</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>J.F.</given-names></name></person-group><article-title>Limited Duration of Remission of Insulin Dependency in Children with Recent Overt Type I Diabetes Treated with Low-Dose Cyclosporin</article-title><source>Diabetes</source><year>1990</year><volume>39</volume><fpage>1264</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.2337/diab.39.10.1264</pub-id><pub-id pub-id-type="pmid">2210078</pub-id></element-citation></ref><ref id="B22-biology-11-01662"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keymeulen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vandemeulebroucke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gorus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Candon</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>2598</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043980</pub-id><pub-id pub-id-type="pmid">15972866</pub-id></element-citation></ref><ref id="B23-biology-11-01662"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keymeulen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gorus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hilbrands</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vandemeulebroucke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van De Velde</surname><given-names>U.</given-names></name><name name-style="western"><surname>Crenier</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Block</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>614</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1644-9</pub-id><pub-id pub-id-type="pmid">20225393</pub-id></element-citation></ref><ref id="B24-biology-11-01662"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherry</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hagopian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wahlen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bode</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aronoff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Teplizumab for Treatment of Type 1 Diabetes (Prot&#233;g&#233; study): 1-year Results from a Randomised, Placebo-controlled Trial</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>487</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60931-8</pub-id><pub-id pub-id-type="pmid">21719095</pub-id><pub-id pub-id-type="pmcid">PMC3191495</pub-id></element-citation></ref><ref id="B25-biology-11-01662"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orban</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>DiMeglio</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Monzavi</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Co-stimulation Modulation with Abatacept in Patients with Recent-onset Type 1 Diabetes: A randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60886-6</pub-id><pub-id pub-id-type="pmid">21719096</pub-id><pub-id pub-id-type="pmcid">PMC3462593</pub-id></element-citation></ref><ref id="B26-biology-11-01662"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pescovitz</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Krause-Steinrauf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>2143</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0904452</pub-id><pub-id pub-id-type="pmid">19940299</pub-id><pub-id pub-id-type="pmcid">PMC6410357</pub-id></element-citation></ref><ref id="B27-biology-11-01662"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludvigsson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Faresj&#246;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hjorth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Axelsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ch&#233;ramy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pihl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaarala</surname><given-names>O.</given-names></name><name name-style="western"><surname>Forsander</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ivarsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>359</volume><fpage>1909</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0804328</pub-id><pub-id pub-id-type="pmid">18843118</pub-id></element-citation></ref><ref id="B28-biology-11-01662"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Long</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>DiMeglio</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Dufort</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Krischer</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Linsley</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>603</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1902226</pub-id><pub-id pub-id-type="pmid">31180194</pub-id><pub-id pub-id-type="pmcid">PMC6776880</pub-id></element-citation></ref><ref id="B29-biology-11-01662"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Hankaniemi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Svedin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sioofy-Khojine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oikarinen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hy&#246;ty</surname><given-names>H.</given-names></name><name name-style="western"><surname>Laitinen</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Hyt&#246;nen</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Flodstr&#246;m-Tullberg</surname><given-names>M.</given-names></name></person-group><article-title>A Coxsackievirus B Vaccine Protects against Virus-Induced Diabetes in an Experimental Mouse Model of Type 1 Diabetes</article-title><source>Diabetologia</source><year>2018</year><volume>61</volume><fpage>476</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4492-z</pub-id><pub-id pub-id-type="pmid">29151123</pub-id><pub-id pub-id-type="pmcid">PMC6448957</pub-id></element-citation></ref><ref id="B30-biology-11-01662"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanatsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name></person-group><article-title>Different Contribution of Class II HLA in Fulminant and Typical Autoimmune Type 1 Diabetes Mellitus</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1626-x</pub-id><pub-id pub-id-type="pmid">15688210</pub-id></element-citation></ref><ref id="B31-biology-11-01662"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsutsumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ikegami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><collab>Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research</collab></person-group><article-title>Class II HLA Genotype in Fulminant type 1 Diabetes: A Nationwide Survey with Reference to Glutamic Acid Decarboxylase Antibodies</article-title><source>J. Diabetes Investig.</source><year>2012</year><volume>3</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.2040-1124.2011.00139.x</pub-id><pub-id pub-id-type="pmid">24843547</pub-id><pub-id pub-id-type="pmcid">PMC4014934</pub-id></element-citation></ref><ref id="B32-biology-11-01662"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawabata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>N.</given-names></name><name name-style="western"><surname>Awata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Osawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in <italic toggle="yes">CSAD/lnc-ITGB7-1</italic> on Chromosome 12q13.13 Associated with Susceptibility to Fulminant Type 1 Diabetes</article-title><source>Diabetes</source><year>2019</year><volume>68</volume><fpage>665</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.2337/db18-0314</pub-id><pub-id pub-id-type="pmid">30552108</pub-id></element-citation></ref><ref id="B33-biology-11-01662"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arany</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strutt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Romanus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Remacle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reusens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.J.</given-names></name></person-group><article-title>Taurine Supplement in Early Life Altered Islet Morphology, Decreased Insulitis and Delayed the Onset of Diabetes in Non-Obese Diabetic Mice</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>1831</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1535-z</pub-id><pub-id pub-id-type="pmid">15502919</pub-id></element-citation></ref><ref id="B34-biology-11-01662"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Briskin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Andrew</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Kilshaw</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Holzmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Hamann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>E.C.</given-names></name></person-group><article-title>Alpha 4 Beta 7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MAdCAM-1</article-title><source>Cell</source><year>1993</year><volume>74</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90305-A</pub-id><pub-id pub-id-type="pmid">7687523</pub-id></element-citation></ref><ref id="B35-biology-11-01662"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanatsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Report of the Japan Diabetes Society&#8217;s Committee on Research on Fulminant Type 1 Diabetes Mellitus: Analysis of Antiviral Antibodies at Disease Onset</article-title><source>J. Jpn. Diab. Soc.</source><year>2008</year><volume>51</volume><fpage>531</fpage><lpage>536</lpage></element-citation></ref><ref id="B36-biology-11-01662"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name></person-group><article-title>Fulminant type 1 Diabetes: A Novel Clinical Entity Requiring Special Attention by All Medical Practitioners</article-title><source>Nat. Clin. Pract. Endocrinol. Metab.</source><year>2007</year><volume>3</volume><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/ncpendmet0351</pub-id><pub-id pub-id-type="pmid">17179928</pub-id></element-citation></ref><ref id="B37-biology-11-01662"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>Fulminant type 1 Diabetes--an Important Subtype in East Asia</article-title><source>Diabetes Metab. Res. Rev.</source><year>2011</year><volume>27</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1236</pub-id><pub-id pub-id-type="pmid">22069293</pub-id></element-citation></ref><ref id="B38-biology-11-01662"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kajio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>A Case of Fulminant Type 1 Diabetes Associated with Significant Elevation of Mumps Titers</article-title><source>Endocr. J.</source><year>2008</year><volume>55</volume><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K07E-126</pub-id><pub-id pub-id-type="pmid">18520103</pub-id></element-citation></ref><ref id="B39-biology-11-01662"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akatsuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gabazza</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Morser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katsuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sumida</surname><given-names>Y.</given-names></name></person-group><article-title>A Case of Fulminant type 1 Diabetes with Coxsackie B4 Virus Infection Diagnosed by Elevated Serum Levels of Neutralizing Antibody</article-title><source>Diabetes Res. Clin. Pract.</source><year>2009</year><volume>84</volume><fpage>e50</fpage><lpage>e52</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2009.03.009</pub-id><pub-id pub-id-type="pmid">19362384</pub-id></element-citation></ref><ref id="B40-biology-11-01662"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>A Case of Fulminant Type 1 Diabetes Mellitus After Influenza B Infection</article-title><source>Diabetes Res. Clin. Pract.</source><year>2008</year><volume>79</volume><fpage>e8</fpage><lpage>e9</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2007.10.030</pub-id><pub-id pub-id-type="pmid">18177974</pub-id></element-citation></ref><ref id="B41-biology-11-01662"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuroiwa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Misawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Terauchi</surname><given-names>Y.</given-names></name></person-group><article-title>A Case of Fulminant Type 1 Diabetes Mellitus Which was Estimated to Triggered by Enterovirus Infection after 25 Years of the Vogt-Koyanagi-Harada (VKH) Disease Onset</article-title><source>J. Jpn. Diab. Soc.</source><year>2016</year><volume>59</volume><fpage>768</fpage><lpage>774</lpage></element-citation></ref><ref id="B42-biology-11-01662"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ohsato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iizuka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>Y.</given-names></name></person-group><article-title>A Case of Fulminant Type 1 Diabetes Mellitus Undergoing Immunosuppression Therapy after Kidney Transplantation with Cytomegalovirus Antigenemia Elevation</article-title><source>J. Jpn. Diab. Soc.</source><year>2009</year><volume>52</volume><fpage>919</fpage><lpage>925</lpage></element-citation></ref><ref id="B43-biology-11-01662"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishibori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koike</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sone</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kamoi</surname><given-names>K.</given-names></name></person-group><article-title>Fulminant Type 1 Diabetes Mellitus Associated with Coxsackie Virus Type A2 Infection: A Case Report and Literature Review</article-title><source>Intern. Med.</source><year>2016</year><volume>55</volume><fpage>643</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.55.5292</pub-id><pub-id pub-id-type="pmid">26984083</pub-id></element-citation></ref><ref id="B44-biology-11-01662"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirtipal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bharadwaj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.G.</given-names></name></person-group><article-title>From SARS to SARS-CoV-2, Insights on Structure, Pathogenicity and Immunity Aspects of Pandemic Human Coronaviruses</article-title><source>Infect. Genet. Evol.</source><year>2020</year><volume>85</volume><fpage>104502</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104502</pub-id><pub-id pub-id-type="pmid">32798769</pub-id><pub-id pub-id-type="pmcid">PMC7425554</pub-id></element-citation></ref><ref id="B45-biology-11-01662"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourgonje</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Abdulle</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Timens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hillebrands</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Navis</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Gordijn</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bolling</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Voors</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Angiotensin-converting Enzyme 2 (ACE2), SARS-CoV-2 and the Pathophysiology of Coronavirus Disease 2019 (COVID-19)</article-title><source>J. Pathol.</source><year>2020</year><volume>251</volume><fpage>228</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/path.5471</pub-id><pub-id pub-id-type="pmid">32418199</pub-id><pub-id pub-id-type="pmcid">PMC7276767</pub-id></element-citation></ref><ref id="B46-biology-11-01662"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miyagawa</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Juto</surname><given-names>P.</given-names></name></person-group><article-title>High Titres of IgA Antibodies to Enterovirus in Fulminant type-1 Diabetes</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1624-z</pub-id><pub-id pub-id-type="pmid">15654603</pub-id></element-citation></ref><ref id="B47-biology-11-01662"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pak</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Eun</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Mcarthur</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.W.</given-names></name></person-group><article-title>Association of Cytomegalovirus Infection with Autoimmune Type 1 Diabe-Tes</article-title><source>Lancet</source><year>1988</year><volume>2</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(88)92941-8</pub-id><pub-id pub-id-type="pmid">2898620</pub-id></element-citation></ref><ref id="B48-biology-11-01662"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honeyman</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>L.C.</given-names></name></person-group><article-title>T-Cell Epitopes in Type 1 Diabetes Autoantigen Tyrosine Phosphatase IA-2: Potential for Mimicry with Rotavirus and Other Environmental Agents</article-title><source>Mol. Med.</source><year>1998</year><volume>4</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1007/BF03401920</pub-id><pub-id pub-id-type="pmid">9606176</pub-id><pub-id pub-id-type="pmcid">PMC2230363</pub-id></element-citation></ref><ref id="B49-biology-11-01662"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippi</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>M.G.</given-names></name></person-group><article-title>Viral Trigger for Type 1 Diabetes</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2863</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.2337/db07-1023</pub-id><pub-id pub-id-type="pmid">18971433</pub-id><pub-id pub-id-type="pmcid">PMC2570378</pub-id></element-citation></ref><ref id="B50-biology-11-01662"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oikarinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tauriainen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Honkanen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oikarinen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vuori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaukinen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rantala</surname><given-names>I.</given-names></name><name name-style="western"><surname>Maki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hyoty</surname><given-names>H.</given-names></name></person-group><article-title>Detection of Enteroviruses in the Intestine of Type 1 Diabetic Patients</article-title><source>Clin. Exp. Immunol.</source><year>2008</year><volume>151</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03529.x</pub-id><pub-id pub-id-type="pmid">17991291</pub-id><pub-id pub-id-type="pmcid">PMC2276929</pub-id></element-citation></ref><ref id="B51-biology-11-01662"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krogvold</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edwin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Buanes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frisk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Skog</surname><given-names>O.</given-names></name><name name-style="western"><surname>Anagandula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korsgren</surname><given-names>O.</given-names></name><name name-style="western"><surname>Undlien</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eike</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S.J.</given-names></name></person-group><article-title>Detection of a Low-grade Enteroviral Infection in the Islets of Langerhans of Living Patients Newly Diagnosed with Type 1 Diabetes</article-title><source>Diabetes</source><year>2015</year><volume>64</volume><fpage>1682</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.2337/db14-1370</pub-id><pub-id pub-id-type="pmid">25422108</pub-id></element-citation></ref><ref id="B52-biology-11-01662"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geravandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maedler</surname><given-names>K.</given-names></name></person-group><article-title>Localization of Enteroviral RNA within the Pancreas in Donors with T1D and T1D-Associated Autoantibodies</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100371</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100371</pub-id><pub-id pub-id-type="pmid">34467248</pub-id><pub-id pub-id-type="pmcid">PMC8385321</pub-id></element-citation></ref><ref id="B53-biology-11-01662"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Insel</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Dabelea</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Krischer</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Lernmark</surname><given-names>&#197;.</given-names></name><etal/></person-group><article-title>Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>1964</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.2337/dc15-1419</pub-id><pub-id pub-id-type="pmid">26404926</pub-id><pub-id pub-id-type="pmcid">PMC5321245</pub-id></element-citation></ref><ref id="B54-biology-11-01662"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>N.G.</given-names></name></person-group><article-title>Enteroviral Infections in the Pathogenesis of Type 1 Diabetes: New Insights for Therapeutic Intervention</article-title><source>Curr. Opin. Pharmacol.</source><year>2018</year><volume>43</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1016/j.coph.2018.07.006</pub-id><pub-id pub-id-type="pmid">30064099</pub-id><pub-id pub-id-type="pmcid">PMC6294842</pub-id></element-citation></ref><ref id="B55-biology-11-01662"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elshebani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Westman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuvemo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Korsgren</surname><given-names>O.</given-names></name><name name-style="western"><surname>Frisk</surname><given-names>G.</given-names></name></person-group><article-title>Effects on Isolated Human Pancreatic Islet Cells after Infection with Strains of Enterovirus Isolated at Clinical Presentation of Type 1 Diabetes</article-title><source>Virus Res.</source><year>2007</year><volume>124</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2006.11.004</pub-id><pub-id pub-id-type="pmid">17169456</pub-id></element-citation></ref><ref id="B56-biology-11-01662"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoyama</surname><given-names>Y.</given-names></name></person-group><article-title>Prediction and Management of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2017</year><volume>13</volume><fpage>701</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1080/17425255.2017.1297422</pub-id><pub-id pub-id-type="pmid">28633581</pub-id></element-citation></ref><ref id="B57-biology-11-01662"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mizukawa</surname><given-names>Y.</given-names></name></person-group><article-title>Drug-Induced Hypersensitivity Syndrome (DiHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Update in 2019</article-title><source>Allergol. Int.</source><year>2019</year><volume>68</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2019.03.006</pub-id><pub-id pub-id-type="pmid">31000444</pub-id></element-citation></ref><ref id="B58-biology-11-01662"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Inaoka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name></person-group><article-title>Association between Anticonvulsant Hypersensitivity Syndrome and Human Herpesvirus 6 Reactivation and Hypogammaglobulinemia</article-title><source>Arch. Dermatol.</source><year>2004</year><volume>140</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1001/archderm.140.2.183</pub-id><pub-id pub-id-type="pmid">14967790</pub-id></element-citation></ref><ref id="B59-biology-11-01662"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tohyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tokura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miyachi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kabashima</surname><given-names>K.</given-names></name></person-group><article-title>Fluctuation of Blood and Skin Plasmacytoid Dendritic Cells in Drug-Induced Hypersensitivity Syndrome</article-title><source>J. Allergy Clin. Immunol.</source><year>2010</year><volume>126</volume><fpage>408</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.06.004</pub-id><pub-id pub-id-type="pmid">20624646</pub-id></element-citation></ref><ref id="B60-biology-11-01662"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hiraharas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sakuma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name></person-group><article-title>Several Herpesviruses Can Reactivate in a Severe Drug-Induced Multiorgan Reaction in the Same Sequential Order as in Graft-Versus-Host Disease</article-title><source>Br. J. Dermatol.</source><year>2006</year><volume>155</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07238.x</pub-id><pub-id pub-id-type="pmid">16882166</pub-id></element-citation></ref><ref id="B61-biology-11-01662"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoneda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kozawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yumioka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shimomura</surname><given-names>I.</given-names></name></person-group><article-title>A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2017</year><volume>102</volume><fpage>2394</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1210/jc.2016-4029</pub-id><pub-id pub-id-type="pmid">28398495</pub-id></element-citation></ref><ref id="B62-biology-11-01662"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onuma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tohyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Osawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><etal/></person-group><article-title>High Frequency of HLA B62 in Fulminant Type 1 Diabetes with the Drug-Induced Hypersensitivity Syndrome</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2012</year><volume>97</volume><fpage>E2277</fpage><lpage>E2281</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-2054</pub-id><pub-id pub-id-type="pmid">23071161</pub-id></element-citation></ref><ref id="B63-biology-11-01662"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gro&#223;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Conzelmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Merle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Steinhart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weil</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koepke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bozzo</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Read</surname><given-names>C.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Infects and Replicates in Cells of the Human Endocrine and Exocrine Pancreas</article-title><source>Nature Metab.</source><year>2021</year><volume>3</volume><fpage>149</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/s42255-021-00347-1</pub-id><pub-id pub-id-type="pmid">33536639</pub-id></element-citation></ref><ref id="B64-biology-11-01662"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirakawa</surname><given-names>J.</given-names></name></person-group><article-title>Pancreatic &#946;-cell fate in subjects with COVID-19</article-title><source>J. Diabetes Investig.</source><year>2021</year><volume>12</volume><fpage>2126</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1111/jdi.13671</pub-id><pub-id pub-id-type="pmcid">PMC8668054</pub-id><pub-id pub-id-type="pmid">34529355</pub-id></element-citation></ref><ref id="B65-biology-11-01662"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jaffr&#233;</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A Human Pluripotent Stem Cell-Based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids</article-title><source>Cell Stem Cell.</source><year>2020</year><volume>27</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.06.015</pub-id><pub-id pub-id-type="pmid">32579880</pub-id><pub-id pub-id-type="pmcid">PMC7303620</pub-id></element-citation></ref><ref id="B66-biology-11-01662"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geravandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahmoudi-aznaveh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Maedler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ardestani</surname><given-names>A.</given-names></name></person-group><article-title>SARS-CoV-2 and Pancreas: A Potential Pathological Interaction?</article-title><source>Trends Endocrinol. Metab.</source><year>2021</year><volume>32</volume><fpage>842</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2021.07.004</pub-id><pub-id pub-id-type="pmid">34373155</pub-id><pub-id pub-id-type="pmcid">PMC8302839</pub-id></element-citation></ref><ref id="B67-biology-11-01662"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Lidsky</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Demeter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bevacqua</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Infects Human Pancreatic &#946; Cells and Elicits &#946; Cell Impairment</article-title><source>Cell Metab.</source><year>2021</year><volume>33</volume><fpage>1565</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.05.013</pub-id><pub-id pub-id-type="pmid">34081912</pub-id><pub-id pub-id-type="pmcid">PMC8130512</pub-id></element-citation></ref><ref id="B68-biology-11-01662"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vandana</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Acklin</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bonnycastle</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Narisu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Erdos</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection induces beta cell transdifferentiation</article-title><source>Cell Metab.</source><year>2021</year><volume>33</volume><fpage>1577</fpage><lpage>1591.e7</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.05.015</pub-id><pub-id pub-id-type="pmid">34081913</pub-id><pub-id pub-id-type="pmcid">PMC8133495</pub-id></element-citation></ref><ref id="B69-biology-11-01662"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathmann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kuss</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kostev</surname><given-names>K.</given-names></name></person-group><article-title>Incidence of Newly Diagnosed Diabetes after COVID-19</article-title><source>Diabetologia</source><year>2022</year><volume>65</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1007/s00125-022-05670-0</pub-id><pub-id pub-id-type="pmid">35292829</pub-id><pub-id pub-id-type="pmcid">PMC8923743</pub-id></element-citation></ref><ref id="B70-biology-11-01662"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuchay</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Gagneja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.K.</given-names></name></person-group><article-title>Short Term Follow-up of Patients Presenting with Acute Onset Diabetes and Diabetic Ketoacidosis during an Episode of COVID-19</article-title><source>Diabetes Metab. Syndr.</source><year>2020</year><volume>14</volume><fpage>2039</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.10.015</pub-id><pub-id pub-id-type="pmid">33113470</pub-id><pub-id pub-id-type="pmcid">PMC7577220</pub-id></element-citation></ref><ref id="B71-biology-11-01662"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.-K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.-M.</given-names></name></person-group><article-title>Binding of SARS Coronavirus to Its Receptor Damages Islets and Causes Acute Diabetes</article-title><source>Acta Diabetol.</source><year>2010</year><volume>47</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s00592-009-0109-4</pub-id><pub-id pub-id-type="pmid">19333547</pub-id><pub-id pub-id-type="pmcid">PMC7088164</pub-id></element-citation></ref><ref id="B72-biology-11-01662"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Kuchay</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.K.</given-names></name></person-group><article-title>Diabetic Ketoacidosis Precipitated by COVID-19: A Report of Two Cases and Review of Literature</article-title><source>Diabetes Metab. Syndr.</source><year>2020</year><volume>14</volume><fpage>1459</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.07.050</pub-id><pub-id pub-id-type="pmid">32771918</pub-id><pub-id pub-id-type="pmcid">PMC7395228</pub-id></element-citation></ref><ref id="B73-biology-11-01662"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paengsai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jourdain</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salvadori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tantraworasin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mary</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Cressey</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Chaiwarith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bowonwatanuwong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bhakeecheep</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kosachunhanun</surname><given-names>N.</given-names></name></person-group><article-title>Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>ofz298</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofz298</pub-id><pub-id pub-id-type="pmid">31660327</pub-id><pub-id pub-id-type="pmcid">PMC6778321</pub-id></element-citation></ref><ref id="B74-biology-11-01662"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name></person-group><article-title>Corticosteroids in diabetes patients infected with COVID-19</article-title><source>Ir. J. Med. Sci.</source><year>2021</year><volume>190</volume><fpage>29</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s11845-020-02287-3</pub-id><pub-id pub-id-type="pmid">32588377</pub-id><pub-id pub-id-type="pmcid">PMC7315113</pub-id></element-citation></ref><ref id="B75-biology-11-01662"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montefusco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ben Nasr</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#8217;Addio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loretelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>I.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abdelsalam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maestroni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dell&#8217;Acqua</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acute and Long-Term Disruption of Glycometabolic Control after SARS-CoV-2 Infection</article-title><source>Nat. Metab.</source><year>2021</year><volume>3</volume><fpage>774</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1038/s42255-021-00407-6</pub-id><pub-id pub-id-type="pmid">34035524</pub-id><pub-id pub-id-type="pmcid">PMC9931026</pub-id></element-citation></ref><ref id="B76-biology-11-01662"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sefik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Junqueira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaffe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Han</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steach</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Israelow</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Inflammasome activation in infected macrophages drives COVID-19 pathology</article-title><source>Nature</source><year>2022</year><volume>606</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04802-1</pub-id><pub-id pub-id-type="pmid">35483404</pub-id><pub-id pub-id-type="pmcid">PMC9288243</pub-id></element-citation></ref><ref id="B77-biology-11-01662"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unsworth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kshirsagar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>R.M.W.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>K.M.</given-names></name></person-group><article-title>New-Onset Type 1 Diabetes in Children during COVID-19: Multicenter Regional Findings in the U.K</article-title><source>Diabetes Care</source><year>2020</year><volume>43</volume><fpage>e170</fpage><lpage>e171</lpage><pub-id pub-id-type="doi">10.2337/dc20-1551</pub-id><pub-id pub-id-type="pmid">32816997</pub-id></element-citation></ref><ref id="B78-biology-11-01662"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tittel</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Rosenbauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kamrath</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reschke</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hammersen</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#246;nkem&#246;ller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pappa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kapellen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holl</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Did the COVID-19 Lockdown Affect the Incidence of Pediatric Type 1 Diabetes in Germany?</article-title><source>Diabetes Care</source><year>2020</year><volume>43</volume><fpage>e172</fpage><lpage>e173</lpage><pub-id pub-id-type="doi">10.2337/dc20-1633</pub-id><pub-id pub-id-type="pmid">32826282</pub-id><pub-id pub-id-type="pmcid">PMC7576433</pub-id></element-citation></ref><ref id="B79-biology-11-01662"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qeadan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Egbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pezzolesi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>T.</given-names></name></person-group><article-title>The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort from the US using the Cerner Real-World Data</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0266809</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0266809</pub-id><pub-id pub-id-type="pmid">35439266</pub-id><pub-id pub-id-type="pmcid">PMC9017888</pub-id></element-citation></ref><ref id="B80-biology-11-01662"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGlacken-Byrne</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>S.E.V.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>R.</given-names></name></person-group><article-title>The SARS-CoV-2 Pandemic Is Associated with Increased Severity of Presentation of Childhood Onset Type 1 Diabetes Mellitus: A Multi-Centre Study of the First COVID-19 Wave</article-title><source>Diabet. Med.</source><year>2021</year><volume>38</volume><fpage>e14640</fpage><pub-id pub-id-type="doi">10.1111/dme.14640</pub-id><pub-id pub-id-type="pmid">34245598</pub-id><pub-id pub-id-type="pmcid">PMC8420510</pub-id></element-citation></ref><ref id="B81-biology-11-01662"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pinhas-Hamiel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>German</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brener</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Azoulay</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Alarming Increase in Ketoacidosis in Children and Adolescents with Newly Diagnosed Type 1 Diabetes during the First Wave of the COVID-19 Pandemic in Israel</article-title><source>Pediatr. Diabetes</source><year>2022</year><volume>23</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/pedi.13296</pub-id><pub-id pub-id-type="pmid">34865288</pub-id></element-citation></ref><ref id="B82-biology-11-01662"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beliard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebekozien</surname><given-names>O.</given-names></name><name name-style="western"><surname>Demeterco-Berggren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rapaport</surname><given-names>R.</given-names></name></person-group><article-title>Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19: Data from a multi-site surveillance registry</article-title><source>J. Diabetes</source><year>2021</year><volume>13</volume><fpage>270</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.13141</pub-id><pub-id pub-id-type="pmid">33283979</pub-id></element-citation></ref><ref id="B83-biology-11-01662"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzeroni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pecora</surname><given-names>F.</given-names></name><name name-style="western"><surname>Motta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruozi</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Giacometti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venezia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iovane</surname><given-names>D.I.</given-names></name></person-group><article-title>Diabetic Ke-Toacidosis at Type 1 Diabetes Onset: Indirect Impact of COVID-19 Pandemic</article-title><source>Acta Biomed.</source><year>2020</year><volume>91</volume><fpage>e2020193</fpage><pub-id pub-id-type="pmid">33525255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23750/abm.v91i4.10943</pub-id><pub-id pub-id-type="pmcid">PMC7927550</pub-id></element-citation></ref><ref id="B84-biology-11-01662"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#380;yga&#322;o</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nowaczyk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Szwilling</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kowalska</surname><given-names>A.</given-names></name></person-group><article-title>Increased Frequency of Severe Diabetic Ketoacidosis at Type 1 Diabetes Onset among Children during COVID-19 Pandemic Lockdown: An Observational Cohort Study</article-title><source>Pediatr. Endocrinol. Diabetes Metab.</source><year>2020</year><volume>26</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.5114/pedm.2020.101003</pub-id><pub-id pub-id-type="pmid">33554490</pub-id></element-citation></ref><ref id="B85-biology-11-01662"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaqeel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aljuraibah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alsuhaibani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huneif</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alsaheel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dubayee</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alsaedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bakkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alnahari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The Impact of COVID-19 Pandemic Lockdown on the Incidence of New-Onset Type 1 Diabetes and Ketoacidosis among Saudi Children</article-title><source>Front. Endocrinol.</source><year>2021</year><volume>12</volume><fpage>669302</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.669302</pub-id><pub-id pub-id-type="pmid">33868185</pub-id><pub-id pub-id-type="pmcid">PMC8049603</pub-id></element-citation></ref><ref id="B86-biology-11-01662"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heinonen</surname><given-names>S.</given-names></name><name name-style="western"><surname>H&#228;stbacka</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#228;&#228;peri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rautiainen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miettinen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Vapalahti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hepojoki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knip</surname><given-names>M.</given-names></name></person-group><article-title>New-Onset Type 1 Diabetes in Finnish Children during the COVID-19 Pandemic</article-title><source>Arch. Dis. Child.</source><year>2022</year><volume>107</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2020-321220</pub-id><pub-id pub-id-type="pmid">34045208</pub-id></element-citation></ref><ref id="B87-biology-11-01662"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name></person-group><article-title>COVID-19 vaccine development: Milestones, lessons and prospects</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>146</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00996-y</pub-id><pub-id pub-id-type="pmid">35504917</pub-id><pub-id pub-id-type="pmcid">PMC9062866</pub-id></element-citation></ref><ref id="B88-biology-11-01662"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Fulminant type 1 diabetes after COVID-19 vaccination</article-title><source>Diabetes Metab.</source><year>2022</year><volume>48</volume><fpage>101324</fpage><pub-id pub-id-type="doi">10.1016/j.diabet.2022.101324</pub-id><pub-id pub-id-type="pmid">35091092</pub-id><pub-id pub-id-type="pmcid">PMC8786596</pub-id></element-citation></ref><ref id="B89-biology-11-01662"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amagai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tamabuchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kambayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>T.</given-names></name></person-group><article-title>Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy</article-title><source>J. Dermatol.</source><year>2022</year><volume>49</volume><fpage>e167</fpage><lpage>e168</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.16304</pub-id><pub-id pub-id-type="pmid">35014070</pub-id></element-citation></ref><ref id="B90-biology-11-01662"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morioka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Natsuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kakutani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ochi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohmura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Emoto</surname><given-names>M.</given-names></name></person-group><article-title>New-onset fulminant type&#8201;1 diabetes after severe acute respiratory syndrome coronavirus&#8201;2 vaccination: A case report</article-title><source>J. Diabetes Investig.</source><year>2022</year><volume>13</volume><fpage>1286</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1111/jdi.13771</pub-id><pub-id pub-id-type="pmcid">PMC9114923</pub-id><pub-id pub-id-type="pmid">35167186</pub-id></element-citation></ref><ref id="B91-biology-11-01662"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toussirot</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>Bereau</surname><given-names>M.</given-names></name></person-group><article-title>Vaccination and Induction of Autoimmune Diseases</article-title><source>Inflamm. Allergy Drug Targets</source><year>2015</year><volume>14</volume><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.2174/1871528114666160105113046</pub-id><pub-id pub-id-type="pmid">26728772</pub-id></element-citation></ref><ref id="B92-biology-11-01662"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.F.</given-names></name></person-group><article-title>New-onset autoimmune phenomena post-COVID-19 vaccination</article-title><source>Immunology</source><year>2022</year><volume>165</volume><fpage>386</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1111/imm.13443</pub-id><pub-id pub-id-type="pmid">34957554</pub-id></element-citation></ref><ref id="B93-biology-11-01662"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Churilov</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Normatov</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Utekhin</surname><given-names>V.J.</given-names></name></person-group><article-title>Molecular Mimicry between SARS-CoV-2 and Human Endocrinocytes: A Prerequisite of Post-COVID-19 Endocrine Autoimmunity?</article-title><source>Pathophysiology</source><year>2022</year><volume>29</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.3390/pathophysiology29030039</pub-id><pub-id pub-id-type="pmid">36136066</pub-id><pub-id pub-id-type="pmcid">PMC9504401</pub-id></element-citation></ref><ref id="B94-biology-11-01662"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.W.</given-names></name></person-group><article-title>Direct involvement of macrophages in destruction of beta-cells leading to development of diabetes in virus-infected mice</article-title><source>Diabetes</source><year>1991</year><volume>40</volume><fpage>1586</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.2337/diab.40.12.1586</pub-id><pub-id pub-id-type="pmid">1661690</pub-id></element-citation></ref><ref id="B95-biology-11-01662"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name></person-group><article-title>Encephalomyocarditis-virus-induced Diabetes Model Resembles &#8220;Fulminant&#8221; Type 1 Diabetes in Humans</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>1854</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1538-9</pub-id><pub-id pub-id-type="pmid">15502917</pub-id></element-citation></ref><ref id="B96-biology-11-01662"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>McClintock</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Onodera</surname><given-names>T.</given-names></name><name name-style="western"><surname>Notkins</surname><given-names>A.L.</given-names></name></person-group><article-title>Virus-induced diabetes mellitus. XVIII. Inhibition by a Nondiabetogenic Variant of Encephalomyocarditis Virus</article-title><source>J. Exp. Med.</source><year>1980</year><volume>152</volume><fpage>878</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1084/jem.152.4.878</pub-id><pub-id pub-id-type="pmid">6252275</pub-id><pub-id pub-id-type="pmcid">PMC2185964</pub-id></element-citation></ref><ref id="B97-biology-11-01662"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mishiba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Pancreatic &#946;-Cell Destruction Induced by Encephalomyocarditis Virus</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>404</volume><fpage>756</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.12.020</pub-id><pub-id pub-id-type="pmid">21144822</pub-id></element-citation></ref><ref id="B98-biology-11-01662"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Onodera</surname><given-names>T.</given-names></name><name name-style="western"><surname>Notkins</surname><given-names>A.L.</given-names></name></person-group><article-title>Virus-Induced Diabetes Mellitus: VIII. Passage of Encephalomyocarditis Virus and Severity of Diabetes in Susceptible and Resistant Strains of Mice</article-title><source>J. Gen. Virol.</source><year>1977</year><volume>37</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-37-2-225</pub-id><pub-id pub-id-type="pmid">200705</pub-id></element-citation></ref><ref id="B99-biology-11-01662"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teshima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kurafuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hirakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyakawa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Reduced Tyk2 Gene Expression in &#946;-Cells Due to Natural Mutation Determines Susceptibility to Virus-Induced Diabetes</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6748</fpage><pub-id pub-id-type="doi">10.1038/ncomms7748</pub-id><pub-id pub-id-type="pmid">25849081</pub-id><pub-id pub-id-type="pmcid">PMC4396380</pub-id></element-citation></ref><ref id="B100-biology-11-01662"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kounoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nagafuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mituyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niho</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>R.</given-names></name></person-group><article-title>Encephalomyocarditis (EMC) Virus-Induced Diabetes Mellitus Prevented by Corynebacterium parvum in Mice</article-title><source>Experientia</source><year>1987</year><volume>43</volume><fpage>430</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1007/BF01940440</pub-id><pub-id pub-id-type="pmid">3032672</pub-id></element-citation></ref><ref id="B101-biology-11-01662"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>Y.W.</given-names></name></person-group><article-title>Role of Macrophages in the Pathogenesis of Encephalomyocarditis Virus-induced Diabetes in Mice</article-title><source>J. Virol.</source><year>1990</year><volume>64</volume><fpage>5708</fpage><lpage>5715</lpage><pub-id pub-id-type="doi">10.1128/jvi.64.12.5708-5715.1990</pub-id><pub-id pub-id-type="pmid">2173763</pub-id><pub-id pub-id-type="pmcid">PMC248710</pub-id></element-citation></ref><ref id="B102-biology-11-01662"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Osawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kounoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>Y.</given-names></name></person-group><article-title>Association of Fulminant type 1 Diabetes with Pregnancy</article-title><source>Diabetes Res. Clin. Pract.</source><year>2003</year><volume>62</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S0168-8227(03)00147-5</pub-id><pub-id pub-id-type="pmid">14581155</pub-id></element-citation></ref><ref id="B103-biology-11-01662"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanatsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Clinical and Immunogenetic Characteristics of Fulminant type 1 Diabetes Associated with Pregnancy</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2006</year><volume>91</volume><fpage>471</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-1943</pub-id><pub-id pub-id-type="pmid">16278271</pub-id></element-citation></ref><ref id="B104-biology-11-01662"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abiru</surname><given-names>N.</given-names></name><name name-style="western"><surname>Awata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikegami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchigata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Osawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kajio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Characteristics and Clinical Course of Type 1 Diabetes Mellitus Related to Anti-Programmed Cell death-1 Therapy</article-title><source>Diabetol. Int.</source><year>2019</year><volume>10</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s13340-018-0362-2</pub-id><pub-id pub-id-type="pmid">30800564</pub-id><pub-id pub-id-type="pmcid">PMC6357237</pub-id></element-citation></ref><ref id="B105-biology-11-01662"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barroso-Sousa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Garrido-Castro</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Min</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krop</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Tolaney</surname><given-names>S.M.</given-names></name></person-group><article-title>Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis</article-title><source>JAMA Oncol.</source><year>2018</year><volume>4</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.3064</pub-id><pub-id pub-id-type="pmid">28973656</pub-id><pub-id pub-id-type="pmcid">PMC5838579</pub-id></element-citation></ref><ref id="B106-biology-11-01662"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatouli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Perdigoto</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Kluger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Gettinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sznol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rushakoff</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>1471</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.2337/dbi18-0002</pub-id><pub-id pub-id-type="pmid">29937434</pub-id><pub-id pub-id-type="pmcid">PMC6054443</pub-id></element-citation></ref><ref id="B107-biology-11-01662"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haddox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Block</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kudva</surname><given-names>Y.C.</given-names></name></person-group><article-title>Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes</article-title><source>BMJ Open Diabetes Res. Care</source><year>2019</year><volume>7</volume><fpage>e000591</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2018-000591</pub-id><pub-id pub-id-type="pmcid">PMC6398813</pub-id><pub-id pub-id-type="pmid">30899528</pub-id></element-citation></ref><ref id="B108-biology-11-01662"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo Preiato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Salvagni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ardizzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pagotto</surname><given-names>U.</given-names></name><name name-style="western"><surname>Pelusi</surname><given-names>C.</given-names></name></person-group><article-title>Diabetes mellitus induced by immune checkpoint inhibitors: Type 1 diabetes variant or new clinical entity? Review of the literature</article-title><source>Rev. Endocr. Metab. Disord.</source><year>2021</year><volume>22</volume><fpage>337</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1007/s11154-020-09618-w</pub-id><pub-id pub-id-type="pmid">33409866</pub-id></element-citation></ref><ref id="B109-biology-11-01662"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriacou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kempegowda</surname><given-names>P.</given-names></name></person-group><article-title>Is Immune Checkpoint Inhibitor-Associated Diabetes the Same as Fulminant Type 1 Diabetes Mellitus?</article-title><source>Clin. Med.</source><year>2020</year><volume>20</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.7861/clinmed.2020-0054</pub-id><pub-id pub-id-type="pmcid">PMC7385772</pub-id><pub-id pub-id-type="pmid">32675150</pub-id></element-citation></ref><ref id="B110-biology-11-01662"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clotman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Specenier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weets</surname><given-names>I.</given-names></name><name name-style="western"><surname>De Block</surname><given-names>C.E.M.</given-names></name></person-group><article-title>Programmed Cell Death-1 Inhibitor-induced Type 1 Diabetes Mellitus</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2018</year><volume>103</volume><fpage>3144</fpage><lpage>3154</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-00728</pub-id><pub-id pub-id-type="pmid">29955867</pub-id></element-citation></ref><ref id="B111-biology-11-01662"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Masaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ozeki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Fulminant Type 1 Diabetes Mellitus with Anti-programmed Cell Death-1 therapy</article-title><source>J. Diabetes Investig.</source><year>2016</year><volume>7</volume><fpage>915</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1111/jdi.12531</pub-id><pub-id pub-id-type="pmcid">PMC5089956</pub-id><pub-id pub-id-type="pmid">27181090</pub-id></element-citation></ref><ref id="B112-biology-11-01662"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Karges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oeverink</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosenbauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holl</surname><given-names>R.W.</given-names></name></person-group><article-title>Ketoacidosis at Diabetes Onset Is Still Frequent in Children and Adolescents. A Multicenter Analysis of 14,664 Patients from 106 Institutions</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>1647</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.2337/dc09-0553</pub-id><pub-id pub-id-type="pmid">19549730</pub-id><pub-id pub-id-type="pmcid">PMC2732146</pub-id></element-citation></ref><ref id="B113-biology-11-01662"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#246;nberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Espes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>P.-O.</given-names></name></person-group><article-title>Better HbA1c during the First Years after Diagnosis of Type 1 Diabetes Is Associated with Residual C Peptide 10 Years Later</article-title><source>BMJ Open Diabetes Res. Care</source><year>2020</year><volume>8</volume><fpage>e000819</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000819</pub-id><pub-id pub-id-type="pmcid">PMC7206906</pub-id><pub-id pub-id-type="pmid">32107263</pub-id></element-citation></ref><ref id="B114-biology-11-01662"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pihoker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilliam</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Hampe</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lernmark</surname><given-names>A.</given-names></name></person-group><article-title>Autoantibodies in diabetes</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><issue>(Suppl. S2)</issue><fpage>S52</fpage><lpage>S61</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.suppl_2.S52</pub-id><pub-id pub-id-type="pmid">16306341</pub-id></element-citation></ref><ref id="B115-biology-11-01662"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchand</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thivolet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dalle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chikh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reffet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vouillarmet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fabien</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cugnet-Anceau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thivolet</surname><given-names>C.</given-names></name></person-group><article-title>Diabetes Mellitus Induced by PD-1 and PD-L1 Inhibitors: Description of Pancreatic Endocrine and Exocrine Phenotype</article-title><source>Acta Diabetol.</source><year>2019</year><volume>56</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/s00592-018-1234-8</pub-id><pub-id pub-id-type="pmid">30284618</pub-id></element-citation></ref><ref id="B116-biology-11-01662"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>D.</given-names></name></person-group><article-title>Nonspecific Hyperamylasemia and Hyperlipasemia in Diabetic Ketoacidosis: Incidence and Correlation with Biochemical Abnormalities</article-title><source>Am. J. Gastroenterol.</source><year>2000</year><volume>95</volume><fpage>3123</fpage><lpage>3128</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.03279.x</pub-id><pub-id pub-id-type="pmid">11095328</pub-id></element-citation></ref><ref id="B117-biology-11-01662"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodriguez-Calvo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>M.</given-names></name></person-group><article-title>Abnormalities of the Exocrine Pancreas in Type 1 Diabetes</article-title><source>Curr. Diabetes Rep.</source><year>2015</year><volume>15</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1007/s11892-015-0653-y</pub-id><pub-id pub-id-type="pmcid">PMC5072278</pub-id><pub-id pub-id-type="pmid">26318606</pub-id></element-citation></ref><ref id="B118-biology-11-01662"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakaki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hiai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Honjo</surname><given-names>T.</given-names></name></person-group><article-title>Establishment of NOD-<italic toggle="yes">Pdcd1</italic><sup>&#8722;/&#8722;</sup> Mice as an Efficient Animal Model of Type I Diabetes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>11823</fpage><lpage>11828</lpage><pub-id pub-id-type="doi">10.1073/pnas.0505497102</pub-id><pub-id pub-id-type="pmid">16087865</pub-id><pub-id pub-id-type="pmcid">PMC1188011</pub-id></element-citation></ref><ref id="B119-biology-11-01662"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Chitnis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Yagita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akiba</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice</article-title><source>J. Exp. Med.</source><year>2003</year><volume>198</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1084/jem.20022125</pub-id><pub-id pub-id-type="pmid">12847137</pub-id><pub-id pub-id-type="pmcid">PMC2196083</pub-id></element-citation></ref><ref id="B120-biology-11-01662"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Latchman</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Buhlmann</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Tomczak</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>A.H.</given-names></name></person-group><article-title>Regulation of PD-1, PD-L1, and PD-L2 Expression during Normal and Autoimmune Responses</article-title><source>Eur. J. Immunol.</source><year>2003</year><volume>33</volume><fpage>2706</fpage><lpage>2716</lpage><pub-id pub-id-type="doi">10.1002/eji.200324228</pub-id><pub-id pub-id-type="pmid">14515254</pub-id></element-citation></ref><ref id="B121-biology-11-01662"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyako</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuromaru</surname><given-names>R.</given-names></name><name name-style="western"><surname>Inuo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>T.</given-names></name></person-group><article-title>PD-1 Gene Haplotype is Associated with the Development of Type 1 Diabetes Mellitus in Japanese Children</article-title><source>Hum. Genet.</source><year>2007</year><volume>121</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/s00439-006-0309-8</pub-id><pub-id pub-id-type="pmid">17203303</pub-id></element-citation></ref><ref id="B122-biology-11-01662"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Rs2227982 and rs2227981 in PDCD1 Gene are Functional SNPs Associated with T1D Risk in East Asian</article-title><source>Acta Diabetol.</source><year>2018</year><volume>55</volume><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1007/s00592-018-1152-9</pub-id><pub-id pub-id-type="pmid">29774466</pub-id></element-citation></ref><ref id="B123-biology-11-01662"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Husby</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Lillevang</surname><given-names>S.T.</given-names></name></person-group><article-title>Association of a Putative Regulatory Polymorphism in the PD-1 Gene with Susceptibility to Type 1 Diabetes</article-title><source>Tissue Antigens</source><year>2003</year><volume>62</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1046/j.1399-0039.2003.00136.x</pub-id><pub-id pub-id-type="pmid">14617032</pub-id></element-citation></ref><ref id="B124-biology-11-01662"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Momotsu</surname><given-names>T.</given-names></name></person-group><article-title>A Novel Subtype of Type 1 Diabetes Mellitus</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1835</fpage><lpage>1837</lpage><pub-id pub-id-type="pmid">10866555</pub-id></element-citation></ref><ref id="B125-biology-11-01662"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Awata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takizawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ichijo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>RIG-I<sup>&#8722;</sup> and MDA5-Initiated Innate Immunity Linked with Adaptive Immunity Accelerates Beta-Cell Death in Fulminant type 1 Diabetes</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><fpage>884</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.2337/db10-0795</pub-id><pub-id pub-id-type="pmid">21289206</pub-id><pub-id pub-id-type="pmcid">PMC3046849</pub-id></element-citation></ref><ref id="B126-biology-11-01662"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group><article-title>Antibody-validated Proteins in Inflamed Islets of Fulminant Type 1 Diabetes Profiled by Laser-capture Microdissection Followed by Mass Spectrometry</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e107664</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0107664</pub-id><pub-id pub-id-type="pmid">25329145</pub-id><pub-id pub-id-type="pmcid">PMC4199548</pub-id></element-citation></ref><ref id="B127-biology-11-01662"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCartney</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Vermi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Otero</surname><given-names>K.</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gilfillan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Unanue</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name></person-group><article-title>RNA Sensor-Induced Type I IFN Prevents Diabetes Caused by a &#946; Cell-Tropic Virus in Mice</article-title><source>J. Clin. Investig.</source><year>2011</year><volume>121</volume><fpage>1497</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1172/JCI44005</pub-id><pub-id pub-id-type="pmid">21403398</pub-id><pub-id pub-id-type="pmcid">PMC3069767</pub-id></element-citation></ref><ref id="B128-biology-11-01662"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kozawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Funahashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Low Gene Expression Levels of Activating Receptors of Natural Killer Cells (NKG2E and CD94) in Patients with Fulminant type 1 Diabetes</article-title><source>Immunol. Lett.</source><year>2013</year><volume>156</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2013.10.004</pub-id><pub-id pub-id-type="pmid">24177169</pub-id></element-citation></ref><ref id="B129-biology-11-01662"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.G.</given-names></name></person-group><article-title>Gene Expression Changes in Patients with Fulminant type 1 Diabetes</article-title><source>Chin. Med. J.</source><year>2011</year><volume>124</volume><fpage>3613</fpage><lpage>3617</lpage><pub-id pub-id-type="pmid">22340212</pub-id></element-citation></ref><ref id="B130-biology-11-01662"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roep</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Kleijwegt</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>van Halteren</surname><given-names>A.G.S.</given-names></name><name name-style="western"><surname>Bonato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boggi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Vendrame</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dotta</surname><given-names>F.</given-names></name></person-group><article-title>Islet Inflammation and CXCL10 in Recent-Onset Type 1 Diabetes</article-title><source>Clin. Exp. Immunol.</source><year>2010</year><volume>159</volume><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2009.04087.x</pub-id><pub-id pub-id-type="pmid">20059481</pub-id><pub-id pub-id-type="pmcid">PMC2819499</pub-id></element-citation></ref><ref id="B131-biology-11-01662"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>A.-K.</given-names></name><name name-style="western"><surname>Korsgren</surname><given-names>O.</given-names></name><name name-style="western"><surname>Frisk</surname><given-names>G.</given-names></name></person-group><article-title>Induction of the Chemokine Interferon-&#947;-Inducible Protein-10 in Human Pancreatic Islets during Enterovirus Infection</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2697</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0429-7</pub-id><pub-id pub-id-type="pmid">16969644</pub-id></element-citation></ref><ref id="B132-biology-11-01662"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Shigihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsumura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Narumi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saruta</surname><given-names>T.</given-names></name></person-group><article-title>Two Cases of &#8220;Fulminant&#8221; Type 1 Diabetes Suggesting Involvement of Autoimmunity</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2003</year><volume>1005</volume><fpage>359</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1196/annals.1288.059</pub-id><pub-id pub-id-type="pmid">14679092</pub-id></element-citation></ref><ref id="B133-biology-11-01662"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takizawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Enterovirus Infection, CXC Chemokine Ligand 10 (CXCL10), and CXCR3 Circuit</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>2285</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.2337/db09-0091</pub-id><pub-id pub-id-type="pmid">19641142</pub-id><pub-id pub-id-type="pmcid">PMC2750208</pub-id></element-citation></ref><ref id="B134-biology-11-01662"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuriya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuwahara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abiru</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Zinc Transporter 8 Autoantibodies in Fulminant, Acute-Onset, and Slow-Onset Patients with Type 1 Diabetes</article-title><source>Diabetes Metab. Res. Rev.</source><year>2011</year><volume>27</volume><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1269</pub-id><pub-id pub-id-type="pmid">22069281</pub-id></element-citation></ref><ref id="B135-biology-11-01662"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shigihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Senda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>K.</given-names></name></person-group><article-title>A Case of Fulminant type 1 Diabetes with Strong Evidence of Autoimmunity</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1482</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.8.1482</pub-id><pub-id pub-id-type="pmid">12145259</pub-id></element-citation></ref><ref id="B136-biology-11-01662"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miyagawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yokono</surname><given-names>K.</given-names></name></person-group><article-title>T Lymphocyte Response against Pancreatic Beta Cell Antigens in Fulminant type 1 Diabetes</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>1285</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1007/s00125-004-1441-4</pub-id><pub-id pub-id-type="pmid">15243701</pub-id></element-citation></ref><ref id="B137-biology-11-01662"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H.</given-names></name></person-group><article-title>A Mimic of Viral Double-Stranded RNA Triggers Fulminant Type 1 Diabetes-Like Syndrome in Regulatory T Cell-Deficient Autoimmune Diabetic Mouse</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>4947</fpage><lpage>4953</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000837</pub-id><pub-id pub-id-type="pmid">21967896</pub-id></element-citation></ref><ref id="B138-biology-11-01662"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haseda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murase-Mishiba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>CD4 + CD45RA &#8722; FoxP3 High Activated Regulatory T Cells Are Functionally Impaired and Related to Residual Insulin-Secreting Capacity in Patients with Type 1 Diabetes</article-title><source>Clin. Exp. Immunol.</source><year>2013</year><volume>173</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1111/cei.12116</pub-id><pub-id pub-id-type="pmid">23607886</pub-id><pub-id pub-id-type="pmcid">PMC3722921</pub-id></element-citation></ref><ref id="B139-biology-11-01662"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haseda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murase-Mishiba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hirano-Kuwata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T.</given-names></name></person-group><article-title>Low CTLA-4 Expression in CD4+ Helper T-Cells in Patients with Fulminant type 1 Diabetes</article-title><source>Immunol. Lett.</source><year>2011</year><volume>139</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2011.05.003</pub-id><pub-id pub-id-type="pmid">21620894</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="biology-11-01662-f001" orientation="portrait"><label>Figure 1</label><caption><p>This schema shows the positioning of fulminant type 1 diabetes (FT1D), ICI-related type 1 diabetes (ICIrT1D) and autoimmune type 1 diabetes (AT1D) based on the presence of islet-related autoantibodies and the rapidity of pancreatic &#946;-cell destruction. ICIrT1D exhibits various phenotypes ranging from FT1D-like to AT1D-like, but the average phenotype is intermediate between FT1D and AT1D, and is considered an independent entity from the etiological approach.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="biology-11-01662-g001.jpg"/></fig><fig position="float" id="biology-11-01662-f002" orientation="portrait"><label>Figure 2</label><caption><p>Aberrant immune response leading to pancreatic &#946;-cell destruction in fulminant type1 diabetes (FT1D) (hypothesis). The development of FT1D following flu-like symptoms suggests the importance of aberrant innate immune responses. Decreased natural killer cell (NK) activity has been reported in FT1D patients, suggesting failure of initial virus elimination. Histopathologically, the marked infiltration of macrophages into pancreatic islets is observed. In mouse models, macrophages are considered to be the major factor in pancreatic &#946;-cell destruction. Furthermore, T cell infiltration into pancreatic islets was observed in histopathological tissue. Repetitive enterovirus infections in FT1D patients suggests the existence of acquired immunity against virus-infected cells. In addition, the fact that islet-associated autoantibodies were positive in some cases suggests the existence of autoimmunity. The decreased regulatory T cell (Treg) activity shown in FT1D patients, and this aberrant innate immune response may make antiviral immunity and autoimmunity more active. Although these characteristic immune profiles are hypothesized to contribute to the rapid and complete destruction of pancreatic &#946;-cells, further investigation is required to make this figure more detailed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="biology-11-01662-g002.jpg"/></fig><table-wrap position="float" id="biology-11-01662-t001" orientation="portrait"><object-id pub-id-type="pii">biology-11-01662-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of fulminant type 1 diabetes and autoimmune type 1 diabetes mellitus (created by authors based on [<xref rid="B3-biology-11-01662" ref-type="bibr">3</xref>]).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FT1D</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AT1D</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age at onset</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wide age range but mainly adult</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wide age range but the peak is in adolescence</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male &#8786; female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male &lt; female</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onset<break/>(duration from onset to DKA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very rapid<break/>(within approximately 7 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute<break/>(within approximately 3 months)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HbA1c level at onset</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~8.7%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very high</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insulin secretion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depleted at onset</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Slight residual for some time after onset</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu-like symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.7%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.9%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevation of pancreatic enzyme levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Frequently</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rarely</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-GAD antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mostly negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Susceptible HLA haplotype in Japanese</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRB1*04:05-DQB1*04:01 DRB1*09:01-DQB1*03:03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRB1*09:01-DQB1*03:03 DRB1*04:05-DQB1*04:01 DRB1*08:02-DQB1*03:02</td></tr></tbody></table></table-wrap><table-wrap position="float" id="biology-11-01662-t002" orientation="portrait"><object-id pub-id-type="pii">biology-11-01662-t002_Table 2</object-id><label>Table 2</label><caption><p>Japanese criteria for definite diagnosis of fulminant type 1 diabetes mellitus (2012) [<xref rid="B11-biology-11-01662" ref-type="bibr">11</xref>].</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Fulminant type 1 diabetes mellitus is confirmed when the following three findings are present:</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(1)</label><p>Occurrence of diabetic ketosis or ketoacidosis soon (approximately 7 days) after the onset of hyperglycemic symptoms (elevation of urinary and/or serum ketone bodies at first visit)</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(2)</label><p>Plasma glucose level &#8805; 16.0 mmol/L (&#8805;288 mg/dL) and glycated hemoglobin level &lt; 8.7% (NGSP value) * at first visit</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(3)</label><p>Urinary C-peptide excretion &lt;10 &#956;g/day or fasting serum C-peptide level &lt;0.3 ng/mL (&lt;0.10 nmol/L) and &lt;0.5 ng/mL (&lt;0.17 nmol/L) after intravenous glucagon (or after meal) load at onset</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other findings in fulminant type 1 diabetes mellitus:</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(A)</label><p>Islet-related autoantibodies, such as antibodies to glutamic acid decarboxylase, islet-associated antigen 2, and insulin, are undetectable in general.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(B)</label><p>Duration of the disease before the start of insulin treatment can be 1 to 2 weeks.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(C)</label><p>Elevation of serum pancreatic enzyme levels (amylase, lipase, or elastase-1) is observed in 98% of the patients.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(D)</label><p>Flu-like symptoms (fever and upper respiratory symptoms, etc.) or gastrointestinal symptoms (upper abdominal pain, nausea, and/or vomiting, etc.) precede the disease onset in 70% of patients.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(E)</label><p>The disease can occur during pregnancy or immediately after delivery.</p></list-item></list>
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>(F)</label><p>Association with HLA <italic toggle="yes">DRB1*04:05-DQB1*04:01</italic> is reported.</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p>* This value is not applicable for patients with previously diagnosed glucose intolerance. NGSP, National Glycohemoglobin Standardization Program.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>